

Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer

The SCORAD Randomized Clinical Trial

Peter J. Hoskin, BSc, MBBS, MD; Kirsten Hopkins, MD, MRCP, MBChB; Vivek Misra, MRCP, MBBS; Tanya Holt, MBBS; Rhona McMenemin, MBChB, MSc; Danny Dubois, MD; Fiona McKinna, MBBS, MRCP; Bernadette Foran, MBChB, MSc; Krishnaswamy Madhavan, MBBS; Carol MacGregor, MBChB; Andrew Bates, BSc, MBBS, MRCP; Noelle O'Rourke, MD; Jason F. Lester, MBBS; Tim Sevitt, MB, BChir, MRCP; Daniel Roos, MBBS, MD; Sanjay Dixit, MBBS, MD; Gillian Brown, MSc; Seonaid Arnott, MedSecDip; Sharon Shibu Thomas, MSc; Sharon Forsyth, BSc; Sandy Beare, PhD; Krystyna Reczko, BSc; Allan Hackshaw, MSc; Andre Lopes, MSc

IMPORTANCE Malignant spinal canal compression, a major complication of metastatic cancer, is managed with radiotherapy to maintain mobility and relieve pain, although there is no standard radiotherapy regimen.

OBJECTIVE To evaluate whether single-fraction radiotherapy is noninferior to 5 fractions of radiotherapy.

DESIGN, SETTING, AND PARTICIPANTS Multicenter noninferiority randomized clinical trial conducted in 42 UK and 5 Australian radiotherapy centers. Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area. Patients were recruited between February 2008 and April 2016, with final follow-up in September 2017.

INTERVENTIONS Patients were randomized to receive external beam single-fraction 8-Gy radiotherapy (n = 345) or 20 Gy of radiotherapy in 5 fractions over 5 consecutive days (n = 341).

MAIN OUTCOMES AND MEASURES The primary end point was ambulatory status at week 8, based on a 4-point scale and classified as grade 1 (ambulatory without the use of aids and grade 5 of 5 muscle power) or grade 2 (ambulatory using aids or grade 4 of 5 muscle power). The noninferiority margin for the difference in ambulatory status was -11%. Secondary end points included ambulatory status at weeks 1, 4, and 12 and overall survival.

RESULTS Among 686 randomized patients (median [interquartile range] age, 70 [64-77] years; 503 (73%) men; 44% had prostate cancer, 19% had lung cancer, and 12% had breast cancer), 342 (49.8%) were analyzed for the primary end point (255 patients died before the 8-week assessment). Ambulatory status grade 1 or 2 at week 8 was achieved by 115 of 166 (69.3%) patients in the single-fraction group vs 128 of 176 (72.7%) in the multifraction group (difference, -3.5% [1-sided 95% CI, -11.5% to ∞]; P value for noninferiority = .06). The difference in ambulatory status grade 1 or 2 in the single-fraction vs multifraction group was -0.4% (63.9% vs 64.3%; [1-sided 95% CI, -6.9 to ∞]; P value for noninferiority = .004) at week 1, -0.7% (66.8% vs 67.6%; [1-sided 95% CI, -8.1 to ∞]; P value for noninferiority = .01) at week 4, and 4.1% (71.8% vs 67.7%; [1-sided 95% CI, -4.6 to ∞]; P value for noninferiority = .002) at week 12. Overall survival rates at 12 weeks were 50% in the single-fraction group vs 55% in the multifraction group (stratified hazard ratio, 1.02 [95% CI, 0.74-1.41]). Of the 11 other secondary end points that were analyzed, the between-group differences were not statistically significant or did not meet noninferiority criterion.

CONCLUSIONS AND RELEVANCE Among patients with malignant metastatic solid tumors and spinal canal compression, a single radiotherapy dose, compared with a multifraction dose delivered over 5 days, did not meet the criterion for noninferiority for the primary outcome (ambulatory at 8 weeks). However, the extent to which the lower bound of the CI overlapped with the noninferiority margin should be considered when interpreting the clinical importance of this finding.

TRIAL REGISTRATION ISRCTN Identifiers: [ISRCTN97555949](https://www.isrctn.com/ISRCTN97555949) and [ISRCTN97108008](https://www.isrctn.com/ISRCTN97108008)

JAMA. 2019;322(21):2084-2094. doi:[10.1001/jama.2019.17913](https://doi.org/10.1001/jama.2019.17913)

[+ Visual Abstract](#)

[+ Supplemental content](#)

[+ CME Quiz at \[jamanetwork.com/learning\]\(http://jamanetwork.com/learning\)](#)

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Peter J. Hoskin, BSc, MBBS, MD, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood HA6 2RN, United Kingdom (peterhoskin@nhs.net).

Spinal canal compression is a common complication of metastatic cancer and affected an estimated 4000 patients in the United Kingdom in 2008 and 25 000 in the United States in 2005.^{1,2} Most patients are treated with radiotherapy, and common practice has been to deliver 20 to 30 Gy in 5 to 10 fractions,^{3,4} with longer fractionation schedules for patients with a better prognosis. However, the evidence for using single-fraction radiotherapy comes from trials based on patients with bone pain from metastatic disease (eg, pelvis, long bones, skull) after excluding metastatic spinal canal compression at diagnosis.^{5,6} A systematic review⁷ on spinal canal compression consisting of only retrospective studies (which tend to be affected by bias and confounding), aside from 1 randomized clinical trial,⁸ reported similar outcomes between single-fraction and multifraction radiotherapy.

Guidelines from the National Institute of Health and Clinical Excellence in England⁹ indicate that radiotherapy may be delivered as a single treatment or several consecutive smaller treatments. The American Society for Radiation Oncology guidelines recommend a single 8-Gy radiation dose for patients with painful spinal sites, particularly if they have limited life expectancy, focusing on pain relief.¹⁰ The US National Comprehensive Cancer Network guidelines refer to radiotherapy to manage spinal canal compression, but do not indicate or recommend any schedule.¹¹

The objective of this study was to evaluate whether single-fraction radiotherapy was noninferior to multifraction radiotherapy for managing spinal canal compression, using mobility as the clinically relevant outcome for patients.

Methods

Study Oversight and Patients

The single-fraction radiotherapy compared to multifraction radiotherapy (SCORAD) trial was approved in the United Kingdom by a single national ethics review board and in Australia by individual review boards for each institution. All patients gave written informed consent. The protocol and statistical analysis plan can be found in [Supplement 1](#) and [Supplement 2](#).

Eligible patients were aged at least 18 years with an estimated life expectancy greater than 8 weeks and proven diagnosis of spinal canal or cauda equina (C1-S2) compression on magnetic resonance imaging or computed tomographic scan, with single or multiple sites of compression. Histological or cytological confirmation of malignancy was required, but not for patients with clinical evidence of prostate cancer, who had to have a serum prostate-specific antigen level greater than 100 µg/L. Patients were excluded if they were able to undergo surgery or chemotherapy or if they had hematological malignancies or glioma, prophylactic treatment in the absence of radiological spinal canal compression, or previous radiotherapy targeting the spine.

Intervention and Randomization Procedure

Patients were randomized in a 1:1 ratio to receive either 20 Gy of external beam radiotherapy in 5 fractions over 5 consecutive days (daily from Monday to Friday) or 8 Gy of radiotherapy in a single fraction. Randomization was performed centrally by the

Key Points

Question Is treatment with a single dose of radiotherapy noninferior to multifraction radiotherapy delivered over 5 days among patients with metastatic cancer who have spinal canal compression?

Findings In a clinical trial of 686 patients, the percentage who were ambulatory at 8 weeks was 69.3% in the single-fraction group vs 72.7% in the multifraction radiotherapy group. The lower CI limit for the risk difference (−11.5%) did not meet the predefined noninferiority margin of −11.0%.

Meaning Treatment with single-fraction radiotherapy did not meet the criterion for noninferiority compared with multifraction radiotherapy for ambulatory response rate at 8 weeks, but consideration should be given to the extent to which the lower bound of the CI overlapped with the noninferiority margin.

University College London Cancer Trials Centre using minimization (with a random element), stratified by center, ambulatory status, primary tumor type, and presence or absence of non-skeletal metastases. Megavoltage radiotherapy was delivered to the compression site with a margin of at least 1 vertebral level above and below. The dose was prescribed at cord depth, using magnetic resonance imaging or imaging at simulation. It was mandated that treatment began within 48 hours of a decision to treat based on diagnostic imaging up to 7 days prior to commencement of treatment. Supportive care was given according to local practice, including steroids and analgesics.

End Points

Patients were assessed in clinic at about 1, 4, 8, 12, and 52 weeks after randomization, unless they were unable or unwilling to attend physically, in which case a health professional from the local hospital contacted them by telephone at these time points. Information about whether outcomes were ascertained in person or by telephone was not collected. These assessments included gathering information regarding ambulatory status, adverse events, and additional treatments received. Information about additional therapies and date of death were also obtained from medical records by research staff.

The primary end point was ambulatory response rate in patients alive at 8 weeks, which was considered a clinically meaningful time point in this population by consensus among the clinical investigators. Ambulatory status was assessed on a 4-point scale, consistent with the World Health Organization performance status, based on the validated Medical Research Council muscle power criteria,¹² in which 1 indicates ambulatory without the use of walking aids and grade 5 of 5 muscle power in all muscle groups; 2, ambulatory with assistance of walking aids or grade 4 of 5 muscle power in any muscle group; 3, unable to walk with no worse than grade 2 of 5 power in all muscle groups or grade 2 of 5 power in any muscle group; and 4, absence (0/5 muscle power) or flicker (1/5 muscle power) of motor power in any muscle group. The ambulatory response rate was defined as the percentage of patients who achieved ambulatory status grade 1 or 2 at 8 weeks (which could be a result of an improvement from a grade 3 or 4 or maintenance of grade 1 or 2 from baseline) using a window of 49 to 62 days.

A secondary end point was ambulatory status assessed at 1, 4, and 12 weeks after randomization (ie, between 7-13, 21-34, and 70-97 days). Other prespecified secondary end points were (1) time to loss of ambulation among patients with ambulatory status 1 or 2 at baseline, measured from randomization until the first occurrence of grade 3 or 4 ambulatory status (those who did not lose ambulation were censored at their last assessment date); (2) time to recovery of ambulation among patients with ambulatory status 3 or 4 at baseline, measured from randomization until the first reported status of grade 1 or 2 (those without improvement were censored at their last assessment date); (3) overall survival at 12 weeks and 12 months and hazard ratio (HR) measured from randomization to death from any cause, with patients censored at the last date seen alive; (4) adverse events classified according to the *Common Terminology Criteria for Adverse Events: Version 4*; (5) adverse events of special interest, which were abnormal bladder function, defined as significant urinary incontinence or urinary retention requiring catheterization, or abnormal bowel function, defined as the occurrence of constipation, diarrhea, or incontinence at 1, 4, 8, and 12 weeks; (6) additional therapies after randomization, which included treatments for spinal canal compression (chemotherapy, hormone therapy, radiotherapy, and surgery) and supportive care for spinal canal compression (analgesics, antiemetics, corticosteroids, physiotherapy, and bisphosphonates); and (7) patient-reported quality of life, including pain (an important measure in spinal canal compression and specifically referred to in guidelines), assessed at baseline and week 1, 4, 8, and 12 using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core Questionnaire (QLQ-C30).¹³ Each quality of life scale ranges from 0 to 100, with higher scores for global health status and functional scales reflecting better performance, but worse performance for symptom scales. Prespecified secondary end points not reported in this article included place and duration of care. We collected the drug names and doses of the steroids and analgesics used as supportive care therapies, and how these changed from baseline to during follow-up, and these were also not analyzed for this article.

Deterioration-free survival was the only post hoc end point, measured among patients who had ambulatory status grade 1 or 2 at baseline until they worsened to grade 3 or 4 during the trial or died, whichever occurred first. Patients whose ambulatory status did not deteriorate to grade 3 or 4 and did not die were censored at the date last seen alive.

Statistical Analysis

Sample Size

The primary trial objective was to show that ambulatory response rate using a single 8-Gy fraction of radiotherapy was noninferior to a total of 20 Gy of radiotherapy over 5 consecutive days (1 fraction per day) at 8 weeks. Assuming an ambulatory response rate (grade 1 or 2) of 75% of participants in both groups and a noninferiority margin of -11% (defined by consensus among the investigators, approved by the grant funder and the funder's external reviewers, and similar to or less than noninferiority margins used in other trials),¹⁴⁻¹⁶ the trial required 386 patients (193 per group) assessable at 8 weeks with

80% power and 1-sided 5% statistical significance. The sample size was inflated to 580 allowing for 33% of participants to die before 8 weeks and later increased to 700 by the independent data monitoring committee because of a higher than anticipated death rate. Investigators remained blinded to the outcomes throughout the study.

Data Analysis

The primary analysis was based on eligible patients who received their randomly assigned treatment and were assessed at 8 weeks. The 8-week ambulatory response rate was compared between groups using the difference in proportions test. A post hoc per-protocol analysis of the primary outcome was done including only patients who received and completed radiotherapy as randomized (**Figure 1**). A post hoc analysis (logistic regression) of the primary outcome involved adjustment by the randomization factors (baseline ambulatory status, primary tumor, and extent of metastases). Logistic regression was also used to evaluate whether the effect of treatment at 8 weeks varied across subgroups with interaction tests. In this analysis, only baseline ambulatory status, primary tumor type, and extent of metastases were prespecified. Ambulatory response was examined among patients who were alive beyond 48 weeks (long-term survivors) in a post hoc analysis.


To evaluate the effect of missing data on the primary analysis, several post hoc sensitivity analyses were performed by (1) extending the definition of the 8-week window from 49 to 62 days to 49 to 69 days by imputing data of patients with a missing assessment at week 8 but with assessments at 1, 4, and 12 weeks; (2) assuming missing data as positive or negative responses; and (3) performing multiple imputation using logistic regression.^{17,18} Details and assumptions used in these sensitivity analyses are outlined in eTable 4 in [Supplement 3](#).

Other post hoc sensitivity analyses were completed. To evaluate the effect of center (one of the stratification factors), the ambulatory response risk difference CIs were derived from a logistic regression with specified standard errors allowing for intrahospital correlation (clustered sandwich estimator), and to evaluate the effect of individuals who died on the ambulatory response risk difference, we made various assumptions: all assumed to be nonresponders, all assumed to be responders, half were assumed to be responders, or the same response rate was assumed as observed in each group.

Post hoc analyses were performed for the primary end point, overall survival, and impaired bladder and bowel function to address concerns associated with the sensitivity of the bladder to radiation. Patients were classified in the following categories in terms of the location of their spinal cord compression: treatment exclusively directed at the spinal cord (C1 to T12), treatment exclusively directed at the cauda equina (L1 to S2), and treatment directed at both the spinal cord and the cauda equina (T6 to L5).

The analysis of time-to-event outcomes was done using the Kaplan-Meier method and Cox regression. These time-to-event analyses included time to loss of ambulation, time to recovery of ambulation, and overall survival. Stratified Cox regression (stratification factors were center, ambulatory status, primary tumor, and presence or absence of nonskeletal

Figure 1. Flow of Participants in a Study of the Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer (SCORAD Trial)



A total of 635 patients (93%) started radiotherapy on the day of randomization and all but 1 patient started radiotherapy within 24 hours of randomization.

metastases) was carried out and the proportional hazards assumption was tested based on Schoenfeld residuals.

Bowel and bladder function were analyzed using logistic regression. Quality of life assessment scale results, including pain scale results, were analyzed using linear regression and mixed modeling. When SCORAD was designed, there were no recommended or clinically relevant noninferiority margins for the EORTC quality of life measures. A prespecified margin of 0.28 was crudely estimated as what would be a statistically significant difference (at a 1-sided 2.5% level of statistical significance) given a trial of 400 patients.

Post hoc analyses also were conducted to confirm the findings from a large trial of patients with any bone metastases who received single-fraction radiotherapy,¹⁹ in which individuals with ambulatory status grade 1 or 2 had improved quality of life compared with individuals with ambulatory status grade 3 or 4.

All comparative effect sizes are for single-fraction vs multifraction radiotherapy. The CIs are 1-sided for the risk difference for ambulatory response and are 2-sided for all other analyses. Noninferiority *P* values are 1-sided and all other *P* values are 2-sided. There was no formal statistical adjustment of *P* values for having multiple secondary outcomes, and therefore these results should be considered exploratory. Data analyses were performed using STATA version 15.1 (StataCorp).

Results

A total of 694 patients were randomized from 42 UK and 5 Australian sites from February 2008 to April 2016, of whom 686 were eligible for inclusion (Figure 1). Baseline characteristics in the total population were balanced (Table 1; eTable 1

Table 1. Baseline Characteristics of Participants in a Study of the Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer

Characteristic	No. (%) Single-Fraction Radiotherapy Group (n = 345)	Multifraction Radiotherapy Group (n = 341)
Age		
Median (range), y	70 (23-96)	70 (33-95)
≥75 y	106 (31)	119 (35)
Sex		
Men	255 (74)	248 (73)
Women	90 (26)	93 (27)
Site of primary cancer		
Prostate	152 (44)	152 (45)
Lung	66 (19)	66 (19)
Breast	39 (11)	40 (12)
Gastrointestinal	35 (10)	38 (11)
Kidney	11 (3)	12 (4)
Skin	9 (3)	6 (2)
Bladder	7 (2)	4 (1)
Other (ie, gynecologic, head and neck, sarcoma, unspecified)	26 (8)	23 (7)
Nonskeletal metastases	159 (46)	156 (46)
No. of spinal cord compression sites		
Single	303 (88)	311 (91)
Multiple	42 (12)	30 (9)
Location of spinal metastases		
Thoracic	232 (67)	230 (67)
Lumbar	72 (21)	65 (19)
Thoracic and lumbar	17 (5)	16 (5)
Sacrum (S1 and S2)	9 (3)	6 (2)
Cervical vertebrae	7 (2)	10 (3)
Cervical and thoracic	5 (1)	8 (2)
Lumbar and sacrum	3 (1)	4 (1)
Not reported	0	2 (1)
WHO performance status ^a	(n = 343)	(n = 337)
0-1 (Best)	97 (28)	94 (28)
2	88 (26)	81 (24)
3	114 (33)	121 (36)
4 (Worst)	44 (13)	41 (12)
Ambulatory status		
Grade 1 (ambulatory without the use of walking aids)	76 (22)	77 (23)
Grade 2 (ambulatory with walking aids)	152 (44)	146 (43)
Grade 3 (unable to walk)	91 (26)	90 (26)
Grade 4 (absence or flicker of motor power in any muscle group)	26 (8)	28 (8)

(continued)

Table 1. Baseline Characteristics of Participants in a Study of the Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer (continued)

Characteristic	No. (%) Single-Fraction Radiotherapy Group (n = 345)	Multifraction Radiotherapy Group (n = 341)
Treatment at baseline	(n = 344)	(n = 341)
None	156 (45)	141 (41)
Hormone therapy within 4 weeks of randomization	96 (28)	97 (28)
Radiotherapy within 6 mo of randomization	36 (10)	39 (11)
Chemotherapy within 4 weeks of randomization	20 (6)	32 (9)
Combination of the above treatments	36 (10)	32 (9)

^a WHO performance status of 0 indicates able to carry out all normal activity without restriction; 1, restricted in strenuous activity but ambulatory and able to carry out light work; 2, ambulatory and capable of all self-care but unable to carry out any work activities and are up and about for greater than 50% of waking hours; 3, symptomatic and in a chair or in bed for greater than 50% of the day but not bedridden; and 4, completely disabled, cannot carry out any self-care, and totally confined to bed or chair.

in Supplement 3) (median [interquartile range] age, 70 [64-77] years; 503 (73%) men; 304 (44%) had prostate cancer). Thoracic spine only (462 of 686 patients [67%]) and lumbar spine only (137 of 686 patients [20%]) were the most common compression sites, and only 4% of compressions involved the cervical spine. Baseline characteristics among patients who were evaluated at 8 weeks were also well balanced (eTable 2 in Supplement 3). Of the 344 patients who were not evaluated at 8 weeks, 255 (74.1%) died before or during the 8-week assessment and the other 89 (25.9%) only had assessments before or after 8 weeks (eTable 3 in Supplement 3). The date of final follow-up was September 8, 2017.

Primary End Point

The primary end point (8-week ambulatory response rate) was available for 342 of 686 (49.9%) patients, and was not significantly different between groups (Table 2). At week 8, ambulatory status grade 1 or 2 was achieved by 115 of 166 patients (69.3%) in the single-fraction group vs 128 of 176 (72.7%) in the multifraction group (difference, -3.5% [1-sided 95% CI, -11.5% to ∞]; *P* value for noninferiority = .06; Table 2 and Figure 2). In the per-protocol analysis, the 8-week ambulatory response rate was 114 of 164 patients (69.5%) in the single-fraction group and 127 of 173 (73.4%) in the multifraction group (difference, -3.9% [1-sided 95% CI, -12.0% to ∞]; *P* value for noninferiority = .07). Post hoc results adjusted for the randomization stratification factors are shown in eTable 4 in Supplement 3.

Prespecified Secondary Outcomes

The differences in ambulatory response rate between the single-fraction and multifraction groups were -0.4% (63.9%


Table 2. Ambulatory Response Rate at 8 Weeks of Participants in a Study of the Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer

Outcome	No. (%)		Absolute Difference (1-Sided 95% CI) ^a	1-Sided P Value for Noninferiority
	Single-Fraction Group (n = 345)	Multifraction Group (n = 341)		
8-Week outcome known	(n = 166)	(n = 176)		
Ambulatory status 1-2	115 (69.3)	128 (72.7)	-3.45 (-11.5 to ∞)	.06
No change in baseline status (grade 1-2) ^b	103 (62.1)	110 (62.5)		
Improved from baseline (3-4 to 1-2)	12 (7.2)	18 (10.2)		
No change in baseline status (3-4) ^b	22 (13.3)	26 (14.8)		
Worsened from baseline (1-2 to 3-4)	29 (17.5)	22 (12.5)		
8-Week outcome unknown ^c	(n = 179)	(n = 165)		
Died before week 8	130	125		
8-Week assessment not available ^c	49	40		

^a 1-Sided 95% CI is reported because the noninferiority hypothesis is based on 1-sided $\alpha = .05$. Single-fraction radiotherapy is not considered noninferior to multifraction radiotherapy if the lower bound of the 1-sided 95% CI is less than -11%.

^b Patients with either grade 1 or 2 at baseline who remain at grade 1 or 2 at 8 weeks (a patient whose status changed from 1 to 2 or vice versa) or patients with grade 3 to 4 who remain at 3 to 4.

^c See eTable 3 in Supplement 3 for more information.

Figure 2. Ambulatory Status of Participants in a Study of the Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer

If the lower boundary of any 1-sided 95% CI is lower than -11% (blue dotted line), single-fraction radiotherapy would not be considered noninferior to multifraction radiotherapy.

vs 64.3%; [1-sided 95% CI, -6.9% to ∞]; *P* value for noninferiority = .004) at 1 week, -0.7% (66.8% vs 67.6%; [1-sided 95% CI, -8.1 to ∞]; *P* value for noninferiority = .01) at 4 weeks, and 4.1% (71.8% vs 67.7%; [1-sided 95% CI, -4.6 to ∞]; *P* value for noninferiority = .002) at 12 weeks (Figure 2 and eFigure 1 in Supplement 3).


The difference in 8-week ambulatory response rate did not vary across subgroups, including patients who had good or poor WHO performance status at baseline (all interaction *P* values were not statistically significant *P* > .05) (eFigure 2 in Supplement 3).

Among patients with ambulatory status 1 or 2 at baseline, there was no statistically significant difference in the time to loss of ambulation between the single-fraction and multifraction group (HR, 1.22 [95% CI, 0.88-1.71]; *P* = .24; eFigure 3 in Supplement 3). The 8-week loss of ambulation rate was 28% (95% CI, 22%-35%) for the single-fraction group and 23% (95% CI, 17%-29%) for the multifraction group. Among patients with ambulatory status 3 or 4 at baseline, there was also no evidence of a statistically significant between-group difference for time to recovery of

ambulation (HR, 1.15 [95% CI, 0.71-1.85]; *P* = .58; eFigure 4 in Supplement 3). The 8-week recovery of ambulation rate was 41% (95% CI, 31%-53%) in the single-fraction group and 36% (95% CI, 26%-49%) in the multifraction group.

Rates of any additional treatment for cancer within 12 months were not significantly different between the single-fraction and multifraction group (104 of 345 patients [30.1%] in the single-fraction group vs 110 of 341 [32.3%] in the multifraction group; risk difference, -2.1% [95% CI, -9.0% to 4.8%]; *P* = .55). The additional treatments included chemotherapy in 41 of 345 patients (11.9%) in the single-fraction group vs 47 of 341 (13.8%) in the multifraction group (difference, -1.9% [95% CI, -6.9% to 3.1%]; *P* = .46), hormone therapy in 44 of 345 patients (12.8%) in the single-fraction group vs 45 of 341 (13.2%) in the multifraction group (difference, -0.4% [95% CI, -5.5% to 4.6%]; *P* = .86), radiotherapy in 43 of 345 patients (12.5%) in the single-fraction group vs 34 of 341 (10.0%) in the multifraction group (difference, 2.5% [95% CI, -2.2% to 7.2%]; *P* = .30), and surgical procedure in 7 of 345 patients (2.0%) in the single-fraction group vs 4 of 341 (1.2%) in the multifraction group (difference, 0.9% [95% CI, -1.0% to 2.7%]; *P* = .37).

Figure 3. Overall Survival of Participants in a Study of the Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer



The date when supportive care therapies started was collected for 604 patients. The rate of postrandomization supportive care therapies was not significantly different between the single-fraction and multifraction group (210 of 304 patients [69.1%] vs 225 of 300 [75%]; risk difference, -5.9% [95% CI, -13.1% to 1.2%]; $P = .11$). Supportive care therapies included analgesics in 146 of 304 patients (48.0%) in the single-fraction group vs 153 of 300 (51%) in the multifraction group (difference, -3.0% [95% CI, -10.9% to 5.0%]; $P = .47$), antiemetics in 52 of 304 patients (17.1%) in the single-fraction group vs 49 of 300 (16.3%) in the multifraction group (difference, 0.8% [95% CI, -5.2% to 6.7%]; $P = .80$); corticosteroids in 110 of 304 patients (36.2%) in the single-fraction group vs 116 of 300 (38.7%) in the multifraction group (difference, -2.5% [95% CI, -10.2% to 5.2%]; $P = .53$), physiotherapy in 76 of 304 patients (25%) in the single-fraction group vs 97 of 300 (32.3%) in the multifraction group (difference, -7.3% [95% CI, -14.5% to -0.1%]; $P = .046$), and bisphosphonates in 14 of 304 patients (4.6%) in the single-fraction group vs 11 of 300 (3.7%) in the multifraction group (difference, 0.9% [95% CI, -2.2% to 4.1%]; $P = .56$).

At week 8, the standardized mean differences in the EORTC QLQ-C30 domains (single-fraction scores minus multifraction scores) adjusted for the baseline values were -0.13 (1-sided 97.5% CI, -0.38 to ∞); P value for noninferiority = .12 for global health, -0.12 (1-sided 97.5% CI, -0.35 to ∞); P value for noninferiority = .09 for physical functioning, and -0.18 (1-sided 97.5% CI, -0.41 to ∞); P value for noninferiority = .19 for emotional functioning. Noninferiority was not met using the prespecified margin of -0.28 for the lower limit. Pain improved from baseline in both groups after starting radiotherapy. Pain scores were not significantly different between the single-fraction and multifraction groups at each time point (eFigure 5 in Supplement 3), with a standardized mean difference of 0.12 at week 8 (1-sided 97.5% CI, ∞ to 0.38); P value for noninferiority = .11, but noninferiority was not met because the upper limit exceeded the prespecified margin of 0.28 .

The median (interquartile range) follow-up was 13.3 (12-50) weeks and the median overall survival was 13.1 weeks, with a total of 529 deaths at the end of follow-up on September 8, 2017 (84.3% were cancer-related deaths; eTable 5 in Supplement 3). The median (interquartile range) survival time was 12.4 (4.6-41.0) weeks in the single-fraction group vs 13.6 (5.9-40.9) weeks in the multifraction group.

The survival rate was 50% (95% CI, 45%-55%) at 12 weeks and 21% (95% CI, 16%-26%) at 12 months for the single fraction group and 55% (95% CI, 49%-60%) at 12 weeks and 18% (95% CI, 13%-23%) at 12 months for the multifraction group. There was no statistically significant difference in survival between the groups (stratified HR, 1.02 [95% CI, 0.74-1.41]; $P = .91$; Figure 3). The proportionality hazards assumption was met ($P = .35$). Also, overall survival was not significantly different across subgroups analyzed (eFigure 6 in Supplement 3).

Adverse Events

The percentage of patients with grade 3 or 4 adverse events was 20.6% in the single-fraction group vs 20.5% in the multifraction group, and the percentages were similar between the groups for each of the adverse events (eTable 6 in Supplement 3). The rates of grade 1 or 2 radiation reactions were 11.6% in the single-fraction group vs 19.4% in the multifraction group, and fatigue was reported by 48.7% of patients in the single-fraction group vs 55.4% in the multifraction group.

Impaired bladder function occurred in 42% of patients in the single-fraction group and 34% in the multifraction group (cumulative risk difference, 7.3% [95% CI, -14.8% to 0.2%]; eTable 7 in Supplement 3). At 8 weeks, 47 of 151 patients (31.1%) in the single-fraction group vs 34 of 166 (20.0%) in the multifraction group experienced abnormal bladder function (risk difference, 10.6% [95% CI, 1.0% to 20.2%]; unadjusted odds ratio [OR], 1.75 [95% CI, 1.05-2.92]; $P = .03$) (adjusted OR, 1.78 [95% CI, 0.93-3.39]; $P = .08$; adjusted for bladder function at baseline, sex, age, baseline ambulatory status, primary tumor, number of spinal canal compression sites, and the extent

of metastases at baseline). Impaired bowel function rates were not significantly different between the groups at any time point, and at week 8 the rates were 59 of 151 patients (39%) in the single-fraction group and 61 of 166 (37%) in the multifraction group, with a risk difference of 2.3% (95% CI, -8.4 to 13.0) and unadjusted OR of 1.10 (95% CI, 0.70-1.74; $P = .67$).

Post Hoc Analyses

Across several sensitivity analyses for the primary end point, including multiple imputation, the point estimate for the ambulatory response rate was not significantly different. The differences ranged from -1.50 to -5.80 in the intention-to-treat population and -2.10 to -5.60 in the per-protocol population (eTable 4 in Supplement 3). The risk difference was -3.45 (1-sided 95% CI, -10.3% to ∞) when estimated from logistic regression with standard errors allowing for intrahospital correlation (eTable 4 in Supplement 3).

The primary analysis excluded patients who died before 8 weeks. However, assuming those patients survived to 8 weeks and all were nonresponders, then the response rate was 39% in the single-fraction group and 43% in the multifraction group (risk difference, -3.7% [1-sided 95% CI, -10.3 to ∞]; P value for noninferiority = .03). Assuming that 50% of the patients who died could have been responders had they survived, the difference was -2.3% (1-sided 95% CI, -8.9% to ∞); P value for noninferiority = .01, and assuming that the patients who died would have had the same response rate as observed in each group, the difference was -3.5% (1-sided 95% CI, -9.6% to ∞); P value for noninferiority = .02).

Deterioration-free survival was not statistically significantly different between the groups (HR, 0.99 [95% CI, 0.80-1.22]; $P = .93$; eFigure 7 in Supplement 3).

Among the subgroup of patients who were alive after 48 weeks ($n = 77$), the baseline characteristics were not significantly different between the groups (eTable 8 in Supplement 3). The 8-week ambulatory response rates were 94.9% in the single-fraction group vs 89.5% in the multifraction group (risk difference, 5.4% [1-sided 95% CI, -6.6 to ∞]). After adjusting for baseline characteristics (ambulatory status, the extent of metastases, and primary tumor type), the risk difference was 0.7% (1-sided 95% CI, -10.0 to ∞).

A total of 232 patients (108 in the single-fraction group and 124 in the multifraction group) received treatment exclusively to the spinal cord, defined as C1 to T12, and 88 patients (47 in the single-fraction group and 41 in the multifraction group) received treatment to the cauda equina, defined as L1 to S2. Twenty patients (11 in the single-fraction group and 9 in the multifraction group) received treatment to both the spinal cord and the cauda equina (T6 to L5). There was no statistically significant between-group difference in ambulatory response rate in the treatment location subgroups, although observed ambulatory response rates for patients whose treatment was directed at the cauda equina were 76.6% in the single-fraction group and 85.4% in the multifraction group (difference, -8.8 [95% CI, -25.0% to 7.5%]; $P = .30$; P value for interaction = 0.65; eTable 9 in Supplement 3). The risk of bladder symptoms in patients receiving radiotherapy to the cauda equina was 34% in the single-dose group vs 10% in the mul-

tifraction group (OR, 4.53 [95% CI, 1.4-15.1]; $P = .014$; P value for interaction = 0.15). No significant difference was found in overall median survival between sites of treatment (13 weeks for C1-T12, 16 weeks for L1-L5, and 13 weeks for T6-L5) or between single-fraction and multifraction groups in each category of spinal canal compression site (P value for interaction = .68).

Patients who were ambulatory responders at 4 or 8 weeks had better quality of life than nonresponders (eTable 10 in Supplement 3).¹⁹ For the single-fraction group, the mean difference in scores at 4 weeks, adjusted for baseline scores, between ambulant versus nonambulant patients was 15.2 (95% CI, 7.5-22.9) for global health, 29.6 (95% CI, 20.9-38.4) for physical functioning, 25.6 (95% CI, 15.2-36.0) for role functioning, and 16.0 (95% CI, 5.3-26.7) for social functioning (all P values $\leq .004$). Similar differences in scores were seen in patients in the multifraction radiotherapy group.

Discussion

In this international noninferiority trial involving patients with metastatic spinal canal compression, treatment with single-fraction radiotherapy, compared with multifraction radiotherapy, did not meet the criterion for noninferiority for achieving ambulatory response status grade 1 or 2 at 8 weeks. The lower bound of the CI (-11.5%) overlapped the noninferiority margin of -11%.

However, for all other time points, the CI limits were within the noninferiority margin, and the observed risk differences between single-fraction and multifraction radiotherapy groups in ambulatory status were small and unlikely to be of clinical importance.

This trial evaluated 15 prespecified secondary end points: ambulatory status at 1, 4, and 12 weeks; loss of ambulation; ambulatory recovery; additional treatment; supportive care; quality of life (global, physical, emotional, and pain dimensions); grade 3 or 4 adverse events; bladder and bowel functioning; and overall survival. None of these outcomes were significantly different between treatment groups.

The EORTC QLQ-C30 outcomes also did not meet the prespecified noninferiority margins (0.28), but this margin had no scientific basis when the trial was designed, and it lacked external validity. However, the EORTC later published boundaries of what values constitute a small clinical standardized mean difference (-0.4 for global health, -0.6 for physical functioning, and 0.5 for pain), which can now be used as independently derived noninferiority margins.²⁰

Only 2 other randomized studies have compared single-fraction radiotherapy with multifraction radiotherapy specifically for managing spinal canal compression, and both were small trials. One single-center 3-group randomized trial from Egypt with 285 patients compared single-fraction radiotherapy with 10 or 20 fractions of radiotherapy, but was not designed for noninferiority.⁸ The other study was designed for noninferiority and compared single-fraction radiotherapy with 5 fractions of radiotherapy, but failed to reach its target accrual.^{14,15,21} Two trials have shown noninferiority of

short-course radiotherapy; 1 trial compared 8 Gy of radiotherapy in 1 fraction with nonstandard 16 Gy of radiotherapy in 2 fractions¹⁶ and the other compared 16 Gy in 2 fractions vs 30 Gy in 8 fractions with a split-course schedule.²¹

The median survival time of 3 months in the current trial is similar to that observed in other studies, specifically studies examining spinal canal compression,^{9,10,13,16,21} in contrast to the median survival time for individuals with any bone metastases of 7 to 9 months. The findings of the current trial are consistent with observational studies of spinal canal compression^{7,14-16,21} and the ICORG-05-03 trial,^{14,15} in which 79% of patients who received single-fraction radiotherapy achieved mobility compared with 68% who received multifraction radiotherapy, but with only 38 patients per group. Among longer-surviving patients, mobility was not significantly different between patients who received single-fraction or multifraction radiotherapy, which is consistent with studies of any bone metastases^{22,23} and in contrast to the proposal that such patients should receive multiple fractions of radiotherapy.²⁴ However, this subgroup was defined using a clinical outcome occurring after randomization, so the results should be interpreted with care.

Use of single-fraction radiotherapy, specifically for patients with spinal canal compression, was low in 2010 ($\leq 18\%$ of clinicians reported using it in an international survey; 8%-11% of US and Canadian clinicians and 17% of European clinicians), which is unlikely to be much higher now.²⁵ A 2013 US study of Surveillance, Epidemiology, and End Results (SEER) Program data and Medicare claims showed a much lower treatment cost per patient for single-fraction radiotherapy (\$1873) than for multifraction radiotherapy (\$4967) for management of bone metastases from prostate cancer.²⁶

Single-fraction radiotherapy has benefits both in terms of patient convenience and reduced costs. In a patient population that has a median survival time of less than 6 months, the opportunity to reduce treatment burden is particularly relevant for patients who have to make multiple hospital visits and pay for travel or hotel costs. Radiotherapy access is often limited, so reducing the number of fractions allows better allocation of resources.²⁷⁻²⁹ Patients and their caregivers sometimes have to travel significant distances to their nearest radiotherapy center, and travel can be a barrier to radiotherapy adherence.^{30,31}

A greater percentage of patients in this study had bladder problems in the single-fraction group than the multifraction group, but this largely occurred when radiotherapy was given for cauda equina compression, which is likely due to its close proximity to the bladder (bladder and bowel function are regulated by the sacral nerves within the cauda equina). The test for interaction between treatment and location of spinal cord compression and their effect on bladder impairment was not statistically significant, but the trial lacked statistical power for subgroup analyses. Taking into account that patients with metastases in the distal spine or cauda equina receiving single-fraction vs multifraction radiation may have higher rates of bladder toxicity, 5 fractions may be preferred for this subgroup.

Limitations

This study has several limitations. First, ambulatory status was assessed either in the clinic or by telephone when patients were unable or unwilling to attend in-person visits. This approach was intended to minimize missing data and categorized mobility based on a 4-point scale. However, no information about which mode was used to ascertain ambulatory status was recorded and it is conceivable that reporting bias influenced assessment of the primary outcome. Second, a substantial percentage of patients died before the 8-week point, with only half of the randomized patients available for the primary end point assessment at 8 weeks, despite an expected survival of greater than 8 weeks being an inclusion criterion. This higher than expected death rate may have led to a slight reduction in study power. However, this early death rate was similar to the rate in other spinal canal compression trials.^{16,21} Furthermore, the observed ambulatory response rate (73%) matched the expected rate for the target patient population (75%), so trial participants included in the analysis at 8 weeks are unlikely to be a biased subgroup with regard to the primary end point. Although the death rate was high, there was no significant difference in the secondary outcomes of ambulatory status at either 1 or 4 weeks after randomization, when the majority of patients were still alive. Third, only 12% of patients had breast cancer, suggesting some potential selection bias, with younger patients who had better prognosis being more likely referred for surgery²³ or longer fractionation schedules instead of this trial; hence, the generalizability of these findings is limited for these patients. Subgroup analysis by tumor type showed no clear evidence that the treatment effect differed significantly between tumor type, although these analyses were not sufficiently powered. No other overt selection criteria were apparent, with 66% of the population being physically mobile at presentation and WHO performance status 1 or 2. Fourth, the assessments of bladder and bowel function were dichotomized as "normal" and "abnormal," instead of having a finer grading to indicate severity, and they were not blinded. Fifth, the multifraction group chosen reflects standard practice in the United Kingdom and several other countries, although in the United States and some European countries 30 Gy of radiotherapy in 10 fractions is more often used.⁴ However, a clinical trial that compared 20 Gy of radiotherapy in 5 fractions with 30 Gy in 10 fractions found no significant difference between them in terms of overall motor response at 1, 3, and 6 months and in overall survival.^{32,33}

Conclusions

Among patients with metastatic solid tumors causing spinal canal compression, treatment with a single radiotherapy fraction, compared with multifraction radiotherapy delivered over 5 days, did not meet the criterion for noninferiority for the primary outcome of being ambulatory at 8 weeks. However, the extent to which the lower bound of the CI overlapped with the noninferiority margin should be taken into account when interpreting the clinical importance of these findings.

ARTICLE INFORMATION

Accepted for Publication: October 9, 2019.

Author Affiliations: Mount Vernon Cancer Centre, Northwood, United Kingdom (Hoskin); University of Manchester, Manchester, United Kingdom (Hoskin); Bristol Centre for Haematology and Oncology Bristol, Bristol, United Kingdom (Hopkins); The Christie Hospital, Manchester, United Kingdom (Misra); Princess Alexandra Hospital, University of Queensland, Brisbane, Australia (Holt); The Freeman Hospital, Newcastle, United Kingdom (McMenemin); Queen Alexandra Hospital, Portsmouth, United Kingdom (Dubois); Royal Sussex County Hospital, Brighton, United Kingdom (McKinna); Weston Park Hospital, Sheffield, United Kingdom (Foran, Brown); Southend University Hospital, United Kingdom (Madhavan, Thomas); Raigmore Hospital, Inverness, United Kingdom (MacGregor, Arnott); Southampton General Hospital, Southampton, United Kingdom (Bates); The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom (O'Rourke); Velindre Cancer Centre, Cardiff, United Kingdom (Lester); Kent Oncology Centre, Maidstone, United Kingdom (Sevitt); Royal Adelaide Hospital, Adelaide, Australia (Roos); University of Adelaide, Adelaide, Australia (Roos); Castle Hill Hospital, Hull, United Kingdom (Dixit); CRUK & UCL Cancer Trials Centre, London, United Kingdom (Forsyth, Beare, Reczko, Hackshaw, Lopes).

Author Contributions: Dr Hoskin and Mr Lopes had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Dr Hoskin and Msrs Hackshaw and Lopes contributed equally to this article.

Concept and design: Dixit, Foran, Forsyth, Hackshaw, Hopkins, Hoskin, Lopes, Misra. **Acquisition, analysis, or interpretation of data:** Arnott, Bates, Beare, Brown, Dubois, Foran, Forsyth, Hackshaw, Holt, Hopkins, Hoskin, Lester, Lopes, MacGregor, Madhavan, McKinna, McMenemin, Misra, O'Rourke, Reczko, Roos, Sevitt, Thomas.

Drafting of the manuscript: Beare, Foran, Forsyth, Hackshaw, Hoskin, Lopes, McMenemin, Misra, Reczko.

Critical revision of the manuscript for important intellectual content: Arnott, Bates, Brown, Dixit, Dubois, Foran, Hackshaw, Holt, Hopkins, Hoskin, Lester, Lopes, MacGregor, Madhavan, McKinna, McMenemin, Misra, O'Rourke, Roos, Sevitt, Thomas.

Statistical analysis: Hackshaw, Lopes.

Obtained funding: Hackshaw, Hoskin, Roos.

Administrative, technical, or material support: Arnott, Beare, Dixit, Foran, Forsyth, Hackshaw, Hoskin, Lester, MacGregor, Reczko, Thomas.

Supervision: Beare, Hackshaw, Hoskin, McKinna, Misra, O'Rourke.

Conflict of Interest Disclosures: Dr Hoskin reported being supported by the National Institute for Health Research Manchester Biomedical Research Centre. Dr Beare reported receiving grants from Cancer Research UK during the conduct of the study. Dr Foran reported receiving personal fees and nonfinancial support from Bristol-Myers Squibb and Merck outside the submitted work. Dr Hackshaw reported receiving

grants from Cancer Research UK during the conduct of the study and support from the University College London and University College London Hospital Biomedical Research Centre. Mr Lopes reported receiving support from the University College London and University College London Hospital Biomedical Research Centre. Dr Misra is the clinical lead for Metastatic Spinal Cord Compression in Manchester, UK. Ms Reczko reported receiving grants from Cancer Research UK during the conduct of the study. Dr Roos reported receiving grants from the Cancer Council Queensland during the conduct of the study. No other disclosures were reported.

Funding/Support: The trial was sponsored by University College London (UCL/09/0199) and coordinated by the Cancer Research UK and UCL Cancer Trials Centre. The trial was funded by CRUK Project Grants C2422/7932 and C2422/A11408 (funder reference CRUK/06/034) and by the Cancer Council Queensland for Australian Site Data Management. UK trial centers were supported by the UK National Institute of Health Research.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 4.

Additional Contributions: We are indebted to the research teams in the 47 sites listed below that contributed to this study and to the patients and families of all the patients who participated. We are also grateful to the independent data monitoring committee (John Yarnold, FRCR [The Institute of Cancer Research, UK]; Patricia Price, FRCP [Imperial College London, UK]; Lucy Kilburn, MSc [The Institute of Cancer Research, UK]) and the trial steering committee (Nick Reed, MBBS [The Beatson West of Scotland Cancer Centre, UK]; Andrew Clamp, PhD [The Christie NHS Foundation Trust]; Fergus Macbeth, FRCR [Velindre Cancer Centre, UK]; Richard Stephens, [UCL MRC Clinical Trials Unit, UK]). None of these individuals received compensation for their work on SCORAD. **Principal investigators:** United Kingdom: Peter Hoskin, MD (Mount Vernon Hospital); Amarnath Challapalli, MD (Bristol Haematology and Oncology Centre); Rhona McMenemin (Freeman Hospital); Danny Dubois, MD (Queen Alexandra Hospital, Portsmouth); Fiona McKinna, MD (Royal Sussex County Hospital); Bernadette Foran, MD (Weston Park Hospital, Sheffield); Vivek Misra, MD (Christie Hospital); Krishnaswamy Madhavan, MD (Southend University Hospital); Carol MacGregor, MD (Raigmore Hospital); Andrew Bates, MD (Southampton General Hospital); Jason F. Lester, MD (Velindre Hospital); Noelle O'Rourke, MD (West of Scotland Beatson Cancer Centre); Tim Sevitt, MD (Kent Oncology Centre); Sanjay Dixit (Castle Hill Hospital); Natasha Mithal, MD (Kent and Canterbury Hospital); David Wilkinson, MD (James Cook University Hospital); Stephanie Gibbs, MD (Queen's Hospital, Romford); Mark Beresford, MD (Royal United Hospital); Sally Morgan, MD (Nottingham City Hospital); Conrad Lewanski, MD (Charing Cross Hospital); Nicola Cornelius, MD (Lincoln County Hospital); Tom Roques, MD (Norfolk and Norwich Hospital); Virginia

Wolstenholme, MD (St Bartholomew's Hospital); Sam Guglani, MD (Cheltenham General Hospital); Mohini Varughese, MD (Musgrove Park Hospital); Sarah Treece, MD (Peterborough District Hospital); Helen O'Donnell, MD (Royal Berkshire Hospital); Delia Pudney, MD (Singleton Hospital); Ian Sayers, MD (New Cross Hospital); Maxine Flubacher, MD (Dorset Cancer Centre, Poole); Liz Toy, MD (Royal Devon and Exeter Hospital); Peter Bliss, MD (Torbay District General Hospital); Alison Franks, MD (University Hospital Coventry); Claire Esler, MD (Leicester Royal Infirmary); Dan Ford, MD (Queen Elizabeth Hospital, Birmingham); Rob Turner, MD (St James's University Hospital); Jonathan Nicoll, MD (Cumberland Infirmary); Geoffrey Coghill, MD (Derriford Hospital); Alan Lamont, MD (Essex County Hospital); Isabel Syndikus, MD (Clatterbridge Centre for Oncology); Simon Gollins, MD (North Wales Cancer Trials Centre); Prakash Ramachandra, MD (Russells Hall Hospital); **Australia:** Daniel Roos, MD (Royal Adelaide Hospital); Tanya Holt, MD (Mater Centre, Brisbane); Bryan Burmeister, MD (Princess Alexandra Hospital, Queensland); Amy Shorthouse, MD (Canberra Hospital); Patrick Dwyer, MD (Lismore Hospital).

REFERENCES

1. Metastatic spinal cord compression in adults: risk assessment, diagnosis and management. Manchester, UK: National Institute for Health and Clinical Excellence; 2008. <https://www.nice.org.uk/guidance/cg75/resources/metastatic-spinal-cord-compression-in-adults-risk-assessment-diagnosis-and-management-pdf-975630102469>. Published November 26, 2008. Accessed August 8, 2019.
2. Schmidt MH, Klimo P Jr, Vriens FD. Metastatic spinal cord compression. *J Natl Compr Canc Netw*. 2005;3(5):711-719. doi:10.6004/jncn.2005.0041
3. Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. *J Clin Oncol*. 1998;16(4):1613-1624. doi:10.1200/JCO.1998.16.4.1613
4. Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. *J Clin Oncol*. 2005;23(9):2028-2037. doi:10.1200/JCO.2005.00.067
5. Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. *J Clin Oncol*. 2007;25(11):1423-1436. doi:10.1200/JCO.2006.09.5281
6. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. *Clin Oncol (R Coll Radiol)*. 2012;24(2):112-124. doi:10.1016/j.clon.2011.11.004
7. Qu S, Meng HL, Liang ZG, et al. Comparison of short-course radiotherapy versus long-course radiotherapy for treatment of metastatic spinal cord compression: a systematic review and meta-analysis. *Medicine (Baltimore)*. 2015;94(43):e1843. doi:10.1097/MD.0000000000001843
8. Abu-Hegazy M, Wahba HA. Single versus multi-fraction radiation treatment for metastatic spinal cord compression: functional outcome study. *Chinese-German J Clin Oncol*. 2011;10:535-540. doi:10.1007/s10330-011-0832-5

9. National Institute for Health and Care Excellence. *Metastatic Spinal Cord Compression in Adults: Risk Assessment, Diagnosis, and Management*. Manchester, UK: National Collaborating Centre for Cancer; 2008. <https://www.nice.org.uk/guidance/cg75/resources/metastatic-spinal-cord-compression-in-adults-risk-assessment-diagnosis-and-management-pdf-975630102469>.
10. Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. *Pract Radiat Oncol*. 2017;7(1):4-12. doi:10.1016/j.prro.2016.08.001
11. National Comprehensive Cancer Network (NCCN) guidelines in oncology. Adult cancer pain. Version 1.2018. January 2018.
12. Aids to the Examination of the Peripheral Nervous System: Memorandum No. 45. London, UK: Medical Research Council; 1976. <https://mrc.ukri.org/documents/pdf/aids-to-the-examination-of-the-peripheral-nervous-system-mrc-memorandum-no-45-superseding-war-memorandum-no-7/>. Accessed August 8, 2019.
13. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst*. 1993;85(5):365-376. doi:10.1093/jnci/85.5.365
14. Lee KA, Dunne M, Small C, et al. (ICORG 05-03): prospective randomized non-inferiority phase III trial comparing two radiation schedules in malignant spinal cord compression (not proceeding with surgical decompression); the quality of life analysis. *Acta Oncol*. 2018;57(7):965-972. doi:10.1080/0284186X.2018.1433320
15. Thirion P, O'Sullivan L, Clayton-Lea A, et al. ICORG 05-03: prospective randomized non-inferiority phase 3 trial comparing two radiation schedules in malignant spinal cord compression not proceeding with surgical decompression. *Int J Radiat Oncol Biol Phys*. 2014;90(5):1263-1264. doi:10.1016/j.ijrobp.2014.10.036
16. Maranzano E, Trippa F, Casale M, et al. 8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. *Radiother Oncol*. 2009;93(2):174-179. doi:10.1016/j.radonc.2009.05.012
17. Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P. A multivariate technique for multiply imputing missing values using a sequence of regression models. *Surv Methodol*. 2001;27:85-95.
18. StataCorp. *Stata 15 Multiple-imputation Manual*. College Station, TX: Stata Press; 2017.
19. McDonald R, Ding K, Brundage M, et al. Effect of radiotherapy on painful bone metastases: a secondary analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23. *JAMA Oncol*. 2017;3(7):953-959. doi:10.1001/jamaoncol.2016.6770
20. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. *J Clin Oncol*. 2011;29(1):89-96. doi:10.1200/JCO.2010.28.0107
21. Maranzano E, Bellavita R, Rossi R, et al. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. *J Clin Oncol*. 2005;23(15):3358-3365. doi:10.1200/JCO.2005.08.193
22. van der Linden YM, Steenland E, van Houwelingen HC, et al. Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: results on survival in the Dutch bone metastasis study. *Radiother Oncol*. 2006;78(3):245-253. doi:10.1016/j.radonc.2006.02.007
23. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. *J Natl Cancer Inst*. 2005;97(1):798-804. doi:10.1093/jnci/dji139
24. Loblaw DA, Mitera G, Ford M, Laperriere NJA. A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. *Int J Radiat Oncol Biol Phys*. 2012;84(2):312-317. doi:10.1016/j.ijrobp.2012.01.014
25. Ryu S, Maranzano E, Schild SE, et al. International survey of the treatment of metastatic spinal cord compression. *J Radiosurg SBRT*. 2015;3(3):237-245.
26. Bekelman JE, Epstein AJ, Emanuel EJ. Single- vs multiple-fraction radiotherapy for bone metastases from prostate cancer. *JAMA*. 2013;310(14):1501-1502. doi:10.1001/jama.2013.277081
27. Borras JM, Dunscombe P, Barton M, et al. Assessing the gap between evidence based indications for radiotherapy and actual practice in European countries. *Value Health*. 2015;18(7):A481-A482. doi:10.1016/j.jval.2015.09.1311
28. Lievens Y, Defourny N, Coffey M, et al; HERO Consortium. Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. *Radiother Oncol*. 2014;112(2):178-186. doi:10.1016/j.radonc.2014.08.034
29. Borras JM, Lievens Y, Dunscombe P, et al. The optimal utilization proportion of external beam radiotherapy in European countries: an ESTRO-HERO analysis. *Radiother Oncol*. 2015;116(1):38-44. doi:10.1016/j.radonc.2015.04.018
30. Oxford Cancer Intelligence Unit National Cancer Intelligence Network. Travel times and distances to radiotherapy centres for head and neck cancer patients in England (2006-2008). http://www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/head_and_neck_cancers/head_and_neck_cancer_hub/resources. Published 2012. Accessed November 9, 2018.
31. Lin CC, Bruinooge SS, Kirkwood MK, et al. Association between geographic access to cancer care and receipt of radiation therapy for rectal cancer. *Int J Radiat Oncol Biol Phys*. 2016;94(4):719-728. doi:10.1016/j.ijrobp.2015.12.012
32. Rades D, Šegedin B, Conde-Moreno AJ, et al. Radiotherapy With 4 Gy × 5 Versus 3 Gy × 10 for metastatic epidural spinal cord compression: final results of the SCORE-2 Trial (ARO 2009/01). *J Clin Oncol*. 2016;34(6):597-602. doi:10.1200/JCO.2015.64.0862
33. Rades D, Conde-Moreno AJ, Cacicedo J, et al. Comparison of two radiotherapy regimens for metastatic spinal cord compression: subgroup analyses from a randomized trial. *Anticancer Res*. 2018;38(2):1009-1015.

From: **Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial**

JAMA. 2019;322(21):2084-2094. doi:10.1001/jama.2019.17913




Figure Legend:

Single-Fraction vs Multifraction Radiotherapy and Ambulatory Status in Spinal Canal Compression Due to Metastatic Cancer

Supplementary Online Content

Hoskin PJ, Hopkins K, Misra V, et al. Effect of single-fraction vs multifraction radiotherapy on ambulatory status among patients with spinal canal compression from metastatic cancer *JAMA*. doi:10.1001/jama.2019.17913

Supplement 1. Trial protocol

This supplementary material has been provided by the authors to give readers additional information about their work.

SCORAD III

**A randomised phase III trial of single fraction
radiotherapy compared to multifraction radiotherapy
in patients with metastatic spinal cord compression**

Trial Sponsor: University College London
Trial Sponsor reference: UCL/09/0199
Trial funder: Cancer Research UK
Funder reference: CRUK/06/034
ISRCTN no: ISRCTN97108008

Protocol version: Final version 4.0
Protocol version date: 03 March 2013



Protocol Version 4.0: 03 March 2013 Authorisation signatures

Name & Role:

Signature:

Date authorised:

Chief Investigator:

Professor Peter Hoskin
Consultant Clinical Oncologist
Mount Vernon Cancer Centre



28th March 2013


For the Sponsor:

Professor Jonathan Ledermann
Director, UCL CTC



8 April 2013

Sandy Beare
Tumour Group Lead, UCL CTC



04/04/2013

Please note:

This trial protocol must not be applied to patients treated outside the SCORAD III trial. UCL CTC can only ensure that approved trial investigators are provided with amendments to the protocol.

Acknowledgements:

The Protocol Writing Group is indebted to the late Venetia Franglen for her help in the development of this protocol in her capacity as Patient Representative.

In addition to the information in the SCORAD III protocol, sites in Australia and New Zealand should also refer to their Group Specific Appendix.
Sites in Australia and New Zealand should refer to BOTH the protocol and the Group Specific Appendix at all times.

Coordinating centre

For general queries, supply of trial documentation and central data management please contact:

The SCORAD III Trial Coordinator
Cancer Research UK & UCL Cancer Trials Centre
90 Tottenham Court Road
London
W1T 4TJ
United Kingdom

Tel: +44 (0) 20 7679 9878
Fax: +44 (0) 20 7679 9871
09:00 to 17:00 Monday to Friday (UK time)
Email: ctc.scorad@ucl.ac.uk

Trial contacts

Chief Investigator: Professor Peter J Hoskin

Address: Mount Vernon Hospital
Centre for Cancer Treatment
Rickmansworth Road
Northwood
Middlesex
HA6 2RN

Trial Management Group (TMG)

Name	Job title	Organisation
Peter J Hoskin	Consultant Clinical Oncologist	Mount Vernon Hospital
Kirsten Hopkins	Consultant Clinical Oncologist	Bristol Haematology & Oncology Centre
Vivek Misra	Consultant Clinical Oncologist	The Christie Hospital, Manchester
Tanya Holt	Radiation Oncologist	Trans Tasman Radiation Oncology Gp (TROG)
Gillian Brown	Supt Research Radiographer	Weston Park Hospital, Sheffield
Seonaid Arnott	Data Manager	The Raigmore Hospital, Inverness
Liz Molloy	Research Nurse	The Christie Hospital, Manchester
Sharon Shibu Thomas	Research Radiographer	Southend University Hospital
Sandy Beare	Tumour Group Lead	UCL CTC
Allan Hackshaw	Trial Statistician	UCL CTC
Sharon Forsyth	Senior Trial Coordinator	UCL CTC
Krystyna Reczko	Trial Coordinator	UCL CTC
Ellice Marwood	Data Manager	UCL CTC

Online randomisation

<https://online.ctc.ucl.ac.uk>

Any technical issues should be emailed to:

ctc.scorad@ucl.ac.uk

ensuring 'SCORAD III randomisation' is included the subject title.

Telephone randomisation

During working hours (Monday to Friday, 09.00 - 17.00 hrs UK time)
randomisations can be conducted with UCL CTC staff on

+44 (0) 20 7679 9880

List of contents

1.0	SCORAD III trial summary.....	6
1.1	Trial schema	7
2.0	Introduction.....	8
2.1	Background.....	8
2.2	Proposed trial	14
2.2.1	Primary endpoint	14
2.2.2	Secondary endpoints	14
2.3	Trial activation.....	15
3.0	Selection of sites and site investigators	16
3.1	Site selection	16
3.1.1	Selection of Principal Investigator and other investigators at sites.....	16
3.1.2	Training requirements for site staff	17
3.2	Site initiation and activation	17
3.2.1	Site initiation	17
3.2.2	Required documentation	17
3.2.3	Site activation letter	18
4.0	Informed consent.....	19
5.0	Selection of patients	21
5.1	Pre-randomisation evaluation	21
5.2	Screening log	21
5.3	Patient eligibility	21
5.3.1	Inclusion criteria	22
5.3.2	Exclusion criteria.....	22
5.3.3	Pregnancy and birth control	22
6.0	Randomisation procedure	24
6.1	Alternative randomisation procedure for UK sites	25
6.2	Alternative randomisation procedure for non-UK sites.....	25
7.0	Trial treatment.....	27
7.1	Treatment planning	28
7.2	Supportive care during treatment.....	28
7.3	Management after treatment withdrawal	28
7.4	Post protocol treatment.....	28
8.0	Assessments.....	29
8.1	Assessments for UK sites.....	29
8.2	Assessments after completion of first 12 weeks of trial	31
8.3	Assessments for non-UK sites	32
9.0	Data management and data handling guidelines	34
9.1	Completing case report forms	34
9.2	Missing data	35
9.3	Timelines for data return	35
9.3.1	Timelines for CRF submissions (UK sites):.....	36
9.4	Data queries.....	36
10.0	Safety reporting	37
10.1	Definitions of Adverse Events	37
10.2	Reporting procedures	38
10.2.1	All Adverse Events (AEs)	38
10.2.2	Serious Adverse Events (SAEs)	40
10.3	SUSARs	42
10.4	Safety monitoring	43
10.5	Pregnancy	43
11.0	Incident reporting	45
12.0	Trial monitoring and oversight	46
12.1	Central monitoring.....	46
12.2	'For cause' on site monitoring	47
12.3	Oversight Committees	48
12.3.1	Trial Management Group (TMG)	48

12.3.2	Trial Steering Committee (TSC)	48
12.3.3	Independent Data Monitoring Committee (IDMC)	48
12.4	Role of UCL CTC	49
13.0	Withdrawal of patients	50
14.0	Trial closure	52
14.1	End of trial	52
14.2	Archiving of trial documentation	52
14.3	Early discontinuation of trial	52
14.4	Withdrawal from trial participation by a site	53
15.0	Statistics	54
15.1	Proposed sample size	54
15.2	Planned analyses	54
15.3	Subgroup analyses	55
15.4	Interim analyses of efficacy	55
15.5	Quality of life assessments	55
16.0	Ethical approvals	56
16.1	Ethical approval	56
16.2	Site approvals	56
16.3	Protocol amendments	57
16.4	Patient confidentiality and data protection	57
17.0	Sponsorship and Indemnity	58
17.1	Indemnity	58
18.0	Funding	59
19.0	Publication policy	60
20.0	References	61
Appendix 1:	Abbreviations	63
Appendix 2:	Definition of secondary endpoints	64
Appendix 3:	Expected adverse events	66
Appendix 4:	Protocol version history	67

1.0 SCORAD III trial summary

SCORAD III: A randomised phase III trial of single fraction radiotherapy compared to multifraction radiotherapy in patients with metastatic spinal cord compression.

Sponsor: University College London: UCL/09/0199

ISRCTN: ISRCTN97108008

Funder: Cancer Research UK: CRUK/06/034

Design: A multicentre, randomised phase III trial.

Overall aim:

To show that ambulatory status using 8Gy in 1 fraction is no worse than with 20Gy in 5 fractions for patients with metastatic spinal cord compression (SCC).

Primary endpoint:

- Ambulatory status at 8 weeks from day 1 of treatment compared to randomisation

Secondary endpoints:

- Recovery of and time to ambulation
- Ambulatory status at 1, 4 and 12 weeks compared to randomisation (where available)
- Maintenance of ambulatory status
- Bladder and bowel function at 1, 4, 8 and 12 weeks from day 1 of treatment compared to randomisation
- Adverse events using RTOG and CTCAE v.4.02 at 1, 4, 8 and 12 weeks from day 1 of treatment
- Quality of life measured using the EORTC QLQ-C30 questionnaire at 1, 4, 8 and 12 weeks from day 1 of treatment compared to randomisation
- Further treatment and SCC retreatment up to 12 months after randomisation
- Duration of care in hospital, hospice, nursing home or home
- Preferred place of care
- Overall survival at 12 weeks and 12 months

Target accrual: 580 patients

Eligibilities:

Inclusion criteria:

- Decision to treat made no more than 48 hours prior to treatment of spinal cord or cauda equina (C1 to S2) compression, based on a full spinal MRI or CT scan confirming compression carried out no more than one week prior to treatment.
- Single site of compression or multiple sites that can be treated within a single radiation treatment field
- Histologically or cytologically confirmed malignant disease, or for prostate tumours a serum PSA >100 ng/ml at any point prior to randomisation (if biopsy done or planned but results not yet available patients may be entered provided all other inclusion and exclusion criteria are met. Biopsy results must be submitted on the relevant CRF page as soon as they are available)
- Life expectancy >8 weeks
- Age ≥18 years
- Able to give written informed consent
- Willing and able to complete assessment forms

Exclusion criteria:

- Patients for whom surgery or chemotherapy treatment is more appropriate
- Patients who are known to be pregnant
- Patients with multiple myeloma, lymphoma, leukaemia or glioma
- Patients undergoing purely prophylactic treatment in the absence of radiological spinal cord or cauda equina compression
- Patients whose spinal compression site has been treated previously with radiotherapy

Planned sites: ~50

Target Countries: United Kingdom, Australia and New Zealand

Treatment summary:

Arm 1: Multiple fraction radiotherapy 20Gy/5f

Arm 2: Single fraction radiotherapy 8Gy/1f


Anticipated duration of recruitment: 4 Years

Duration of patient follow up: 12 months

Definition of trial end:

12 months post randomisation of last patient or the death of the last surviving patient, whichever event occurs first

1.1 Trial schema



2.0 Introduction

2.1 Background

Spinal cord compression (SCC) is a common complication of metastatic cancer affecting around 4,000 patients in the UK annually, and is a major cause of morbidity resulting in pain, loss of mobility and of sphincter control. Whilst chemotherapy and surgery may be considered, for the vast majority of patients the treatment of choice is radiotherapy, the aim of which is to preserve or recover neurological function and prevent further progression of symptoms. Current common practice is to use between 20 and 30Gy in 5 to 10 fractions although many patients with poor performance status are treated with single doses of 8 to 10Gy. There is no standard fractionation schedule. Since the life expectancy of these patients is short (4 to 6 months), any prolonged treatment must be justified by randomised clinical trial based evidence. The aim of this trial is to determine whether single fraction radiotherapy is as effective as multifraction radiotherapy in terms of ambulatory status, function, quality of life, adverse events and survival in patients with SCC. Patients admitted to hospital for SCC and for whom radiotherapy is recommended will be randomised to either multifraction or single fraction radiotherapy. Patients will be assessed at 1, 4, 8 and 12 weeks after treatment.

The majority of SCC cases arise due to either extradural compression or invasion of the spinal cord by metastases from an adjacent vertebral body. The physiology of spinal cord and cauda equina damage is thought to relate initially to venous obstruction and oedema rather than direct physical pressure causing the initial symptoms¹ (direct pressure causing neuropraxia, axonal fracture or arterial occlusion causing infarction are generally thought to be irrecoverable). It is therefore entirely conceivable that minimal tumour shrinkage allowing restoration of venous drainage and a period of growth delay for a matter of months is adequate treatment for the majority of patients with metastatic spinal cord compression.

The standard treatment after histological and radiological confirmation of SCC is radiotherapy. Exceptions are patients with non-Hodgkin's lymphoma or germ cell tumours where primary chemotherapy may be appropriate, and those cases where there is gross spinal instability that requires surgery. New evidence suggests that those with a localised block and no metastatic disease elsewhere may also benefit from initial surgical decompression².

Nevertheless for the vast majority of patients the treatment of choice is radiotherapy, and standard radiotherapy techniques employ a direct posterior field and a treatment volume defined by the site of compression and a margin of one to two vertebral bodies above and below this. In the past myelography was used to define the site of block but magnetic resonance imaging (MRI) is now the investigation of choice giving optimum definition of the extent of spinal disease.

Studies comparing multiple fractions

Currently, there is no standard fractionation schedule for treating SCC. Common practice in the UK is to use between 20 and 30Gy in 5 to 10 fractions. Prolonged schedules delivering 45Gy in 4.5 weeks have been described but there is no evidence of an advantage to these higher dose schedules³. A retrospective nonrandomised comparison of 30Gy in 10 fractions with 37.5Gy in 15 fractions and 40Gy in 20 fractions revealed no difference in functional outcome between the three groups⁴. The only randomised trial compared 16Gy in 2 fractions with a split course treatment of 15Gy in 3 fractions followed after an interval by 15Gy in 5 fractions⁵. The results of this reported 72% of patients able to walk after treatment with no difference between the two radiation dose arms, however, neither of these radiotherapy doses would be considered standard.

Evidence for single fractions

A single fraction of 8 to 10Gy will achieve substantial tumour cell kill, which is illustrated by the very small proportion of cells remaining after only 2Gy (SF2). Typical values from human cell lines relevant to this population are 0.30 for breast

cancer and 0.18 for squamous lung cancer⁶. Such doses may therefore be entirely compatible with effective treatment.

In other palliative situations hypofractionation has proven to be as effective as the more traditional lengthy fractionated schedules: in particular for bone pain⁷, palliation of non-small cell lung cancer⁸ and cerebral metastases⁹.

There are six published series in which single fractions of radiation have been used to treat spinal cord compression:

- Researchers from the Christie Hospital¹⁰ reported a series of 100 consecutive patients treated with radiotherapy alone and 25 who received postoperative irradiation following laminectomy. Of these, 104 received single fractions of 12.5 to 15Gy, 10 received single fractions of 5 to 10Gy and 11 received a fractionated schedule. In the 100 patients treated with radiotherapy alone, 8 out of 9 ambulatory patients retained mobility, 14 out of 25 non-ambulatory patients were subsequently able to walk and 7 out of 66 paraplegic patients improved, 6 becoming ambulatory. As in other series the only significant factor predicting a good outcome in these patients was pretreatment neurological status.
- A smaller series of patients¹¹ treated with a single fraction of 10Gy reported an overall improvement in motor function in 15 out of 24 patients.
- A more recent series of 102 patients found no difference in outcome between the 32% who received single fraction radiotherapy compared to the remainder of the cohort who received fractionated treatment despite better performance status in this latter group¹². Overall 71% were ambulant at 2 months after treatment. These figures compare with those published in a review of radiotherapy in spinal cord compression in which 79% of ambulant patients retained function, and 42% of those presenting with paraparesis became ambulant¹³.
- A further series of 199 patients treated with 8Gy in a single fraction reported that mobility was regained in 26% of non-ambulatory patients, and only 17% deteriorated; results were compared to a multifraction series¹⁴.

- A retrospective analysis of 204 patients treated with either a single dose of 8Gy or 30Gy in 10 fractions showed no significant differences between the schedules for motor function or ambulatory status¹⁵.
- A pooled analysis from four European countries including one from the UK analysed data from 1,304 patients receiving one of five radiation schedules: 8Gy single dose, 20Gy in 5 fractions, 30Gy in 10 fractions, 37.5Gy in 15 fractions and 40Gy in 20 fractions. This concluded that all five schedules produced similar functional outcome¹⁶.

An Italian group has also recently presented a further trial of 8Gy in a single fraction vs. 16Gy in 2 fractions in 96 patients with poor performance status reporting a 76% ambulation rate after radiotherapy with no difference between the two arms at a median follow up of 6 months¹⁷, but this does not really address the question of whether single is as good as more standard multifractionated regimens.

The recently published UK NICE guidelines¹⁸ highlighted the poor quality evidence currently available for radiotherapy schedules in SCC as follows: 'given the low quality of case series studies conclusions are limited about the effectiveness of different radiotherapy regimens'. It went on to conclude 'Radiotherapy may be delivered as a single treatment or a number of consecutive smaller treatments (fractionation). For patients with MSEC current clinical practice is to give fractionated radiotherapy, generally in five or ten fractions, especially for patients after surgery and for those with good prognostic factors, for whom the duration of tumour response may be important. The use of short fractionation regimens is the subject of continuing research'. In its summary conclusions it stated: 'Further research should investigate what are the most clinically and cost effective regimens of radiotherapy to treat patients with established MSEC'. These extracts highlight the recognition by NICE that research is urgently needed to define optimal radiotherapy fractionation in SCC. This will be addressed by SCORAD III.

Three systematic reviews have been carried out in this field more recently^{19, 20, 21}. Loblaw concluded 'there are very few papers of high methodological quality in the literature. More studies are needed to satisfy the validity of many of the clinical decisions that are made today with regard to the management of malignant spinal cord compression'. At 2009, there are currently no RCTs listed on the International Cancer Research Portfolio (ICRP) website. The Cochrane Review, updated in 2008, again highlights the paucity of data available: only six RCTs addressing radiotherapy, surgery and steroid use were identified, none considering radiotherapy fractionation. The authors conclude: 'Limited evidence suggests that short courses of radiotherapy suffice in patients with unfavourable histologies or a predicted survival of less than six months. There are no RCTs to draw conclusions regarding the optimal radiotherapy dose in good prognostic patients.' and recommends that 'Adequately powered, multinational RCTs are needed'.

Risk of myelopathy

There is extensive literature on the use of single fractions of 8 or 10Gy for uncomplicated spinal metastases, none of which has identified a detectable risk of myelopathy. A retrospective analysis of 465 patients treated for spinal cord compression identified only one possible case of myelopathy in a patient receiving 16Gy in 2 fractions, becoming symptomatic 19 months after initial presentation²². In addition the estimated risk of radiation myelopathy from palliative radiotherapy for non small cell lung cancer was calculated using over 1,000 patients taking part in a series of MRC trials²³. These patients will have had similar doses of radiotherapy to the spinal cord. Only five patients were reported as having radiation myelopathy, two who had received 17Gy/2f and three who had 39Gy/13f, but none in patients who received 10Gy/1f. The overall cumulative risk was estimated as 0.8% at year 1 and 1.5% at year 2. Thus the risk of radiation myelopathy appears negligible.

The life expectancy of these patients is short (4 to 6 months) and so any prolonged treatment must be clearly justified by randomised clinical trial based evidence. There is no evidence to suggest that single fraction radiotherapy for spinal cord

compression would be disadvantageous. If it is proven to be equivalent to multifraction radiotherapy, this would enable a major change in clinical practice with advantages both for the patient in terms of treatment duration and hospital stay, and with obvious socioeconomic advantages.

2.2 Proposed trial

The objectives are to evaluate multifraction radiotherapy against single fraction radiotherapy in terms of ambulatory status, bladder and bowel function, quality of life, further treatment, adverse events and survival. The trial will be a multicentre, randomised (1:1) phase III trial.

The patients will be randomised to receive either Arm 1: 20Gy over 5 fractions, or Arm 2: 8Gy in a single fraction.

2.2.1 Primary endpoint

- Ambulatory status at 8 weeks from day 1 of treatment compared to randomisation.

2.2.2 Secondary endpoints

- Recovery of and time to ambulation
- Ambulatory status at 1, 4 and 12 weeks compared to randomisation (where available)
- Maintenance of ambulatory status
- Bladder and bowel function at 1, 4, 8 and 12 weeks from day 1 of treatment compared to randomisation
- Adverse events using the Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria and Common Terminology Criteria for Adverse Events (CTCAE) v4.02 at 1, 4, 8 and 12 weeks from day 1 of treatment
- Quality of life measured using the EORTC QLQ-C30 questionnaire at 1, 4, 8 and 12 weeks from day 1 of treatment compared to randomisation
- Further treatment and SCC retreatment up to 12 months after randomisation
- Duration of care in hospital, hospice, nursing home or home
- Preferred place of care
- Overall survival to 12 weeks and 12 months

2.3 Trial activation

UCL CTC will ensure that all trial documentation has been reviewed and approved by all relevant bodies and that the following have been obtained prior to activating the trial:

- Research Ethics Committee approval
- Adoption into NIHR portfolio
- NHS permission
- Adequate funding for central coordination
- Confirmation of sponsorship
- Adequate insurance provision

3.0 Selection of sites and site investigators

3.1 Site selection

In this protocol, trial “site” refers to the hospital where trial related activities are conducted.

Sites must be able to comply with:

- Trial treatments, imaging, clinical care, follow up schedules and all requirements of the trial protocol

NB: Sites can opt out of the multifraction schedule and use their own multifraction schedule in this trial but they must notify UCL CTC of this on the site registration form.

- UK sites: Requirements of the Research Governance Framework, 2nd Edition 2005
- Data collection requirements

Non-UK sites must be able to comply with:

- All local regulations governing clinical trials in radiotherapy.
Where applicable a non-UK site should refer to their group specific appendix for additional details.

3.1.1 Selection of Principal Investigator and other investigators at sites

Sites must have an appropriate Principal Investigator (PI) i.e. a health care professional authorised by the site and ethics committee (if applicable) to lead and coordinate the work of the trial on behalf of the site. Other investigators at site wishing to participate in the trial must be trained and approved by the PI. All investigators must be appropriately qualified health professionals and have experience of treating SCC.

3.1.2 Training requirements for site staff

All site staff must be appropriately qualified by education, training and experience to perform the trial related duties allocated to them, which must be recorded on the site delegation log.

CVs for all staff **must be kept up to date** and signed and dated copies held in the Investigator Site File (ISF). An up to date, signed copy of the CV for the PI must be forwarded to UCL CTC upon request.

GCP training is required for all staff responsible for trial activities at UK sites. The frequency of repeat training may be dictated by the requirements of their employing institution, or 2 yearly where the institution has no policy, and more frequently when there have been updates to the legal or regulatory requirements for the conduct of clinical trials.

For non-UK sites the frequency of GCP training will be dictated by that country's policy on repeat training.

GCP training will be provided by the Country Coordinating Centre (CCC) as part of site initiation for sites in countries where GCP training is not mandatory.

3.2 Site initiation and activation

3.2.1 Site initiation

Before a site is activated, the UCL CTC trial team will arrange a site initiation with the site, which the PI and site research team must attend. The site will be trained in the day to day management of the trial and essential documentation required for the trial will be checked.

Site initiation will be performed for each site, by either a visit to site or by teleconference. .

3.2.2 Required documentation

The following documentation must be submitted to UCL CTC prior to a site being activated by UCL CTC:

- Trial specific Site Registration Form (identifying relevant local staff)
- All relevant institutional approvals, including local Research and Development (R&D) approval, or equivalent for non-UK sites

- For UK sites: a signed Clinical Trial Site Agreement (CTSA) between the Sponsor and the relevant institution (usually an NHS Trust)
- A completed site delegation log, signed and dated by the PI
- A copy of the PI's CV that is signed and dated
- For non-UK sites:
 - A signed International Clinical Trials Site Agreement (ICTSA).
 - For countries with a Country Coordinating Centre (CCC) a signed International Country Coordinating Centre Agreement and a signed clinical trial agreement between the CCC and the relevant institution.

3.2.3 Site activation letter

Once the UCL CTC trial team has received all required documentation and the site has been initiated, a site activation letter will be issued to the PI, at which point the site may start to approach patients.

Once the site has been activated by UCL CTC, the PI is responsible for ensuring:

- Adherence to the most recent version of the protocol
- All relevant site staff are trained in the protocol requirements
- Appropriate recruitment and medical care of patients in the trial
- Timely completion and return of Case Report Forms (CRFs) (including assessment of all adverse events)
- Prompt notification and assessment of all serious adverse events
- That the site has facilities to provide **24 hour medical advice** for trial patients.

4.0 Informed consent

Sites are responsible for assessing a patient's capability to give informed consent. Sites must ensure that all patients have been given the current version of the patient information sheet, are fully informed about the trial and have confirmed their willingness to take part in the trial by signing a consent form.

All efforts should be made to enter all eligible patients into the trial, however the Site must assess a patient's ability to understand verbal explanations and written information in English. As patients for this trial are consented and randomised in an emergency setting, if local interpreters are not available in the time before approaching and treating a potential patient at the site, and whenever the patient is contacted, and fully informed consent is not deemed possible, the patient should not be considered for the trial.

The PI, or, where delegated by the PI, other appropriately trained site staff are required to provide a full explanation of the trial and all relevant treatment options to each patient prior to trial entry. During these discussions the current approved patient information sheet for the trial should be discussed with the patient.

A minimum of 30 minutes must be allowed for the patient to consider and discuss participation in the trial. Written informed consent on the current approved version of the consent form for the trial must be obtained before any trial specific procedures are performed. The discussion and consent process must be documented in the patient notes.

All Site staff are responsible for:

- checking that the correct (current approved) version of the patient information sheet and consent form are used
- checking that information on the consent form is complete and legible
- checking that the patient has completed and initialled all relevant sections and signed and dated the form
- checking that an appropriate member of staff has countersigned and dated the consent form to confirm that they provided information to the patient
- checking that an appropriate member of staff has made dated entries in the patient's medical notes relating to the informed consent process (i.e. information given, consent signed etc.)

- giving the patient a copy of their signed consent form, patient information sheet and patient contact card
- following randomisation: adding the patient trial number to all copies of the consent form, which should be filed in the patient's medical notes and ISF and, for UK patients only, sending a copy to UCL CTC

The right of the patient to refuse to participate in the trial without giving reasons must be respected. All patients are free to withdraw at any time (also refer to section 13.0: Withdrawal of patients).

In addition, Non-UK Sites will need to consent patients to the trial according to local practice and regulatory and/or ethical requirements.

An Informed Consent Form Log will also be maintained and completed by site. A copy of the informed consent log must be returned to the CCC for forwarding to UCL CTC at the frequency detailed in the trial monitoring plan or when requested (see also section 12.1 Central monitoring).

5.0 Selection of patients

5.1 Pre-randomisation evaluation

The following assessments or procedures are required to evaluate the suitability of patients for the trial or to provide baseline data:

- A full spine MRI or CT scan to confirm spinal cord compression, no more than one week before treatment
- Assessment of ambulatory status (see appendix 2.1)
- Confirmation of bladder and bowel continence
- Patient completion of the Quality of Life questionnaire

In addition, all patients should have histological or cytological confirmation of malignant disease, or for prostate tumours a serum PSA of >100ng/ml **at any point prior to randomisation**. However, if these results are not yet available at the time of randomisation, but a biopsy has already been done or is planned, patients can be recruited as long as they meet all of the inclusion and exclusion criteria (see section 5.3 below). Sites must ensure that the biopsy results are submitted to UCL CTC on the relevant CRF page as soon as they are available.

Any non-routine procedures must not be performed prior to informed consent being taken.

5.2 Screening log

A screening log must be maintained by the site and kept in the ISF. This must record each patient screened for the trial and must include all patients identified with SCC together with the reasons why they were not randomised if this was the case.

The log must be sent to UCL CTC when requested, with patient identifiers removed prior to sending.

5.3 Patient eligibility

There will be no exception to the eligibility requirements at the time of randomisation. Queries in relation to the eligibility criteria must be addressed prior

to randomisation. Patients are eligible for the trial if the inclusion criteria are met and none of the exclusion criteria apply.

5.3.1 Inclusion criteria

- Decision to treat made no more than 48 hours prior to treatment of spinal cord or cauda equina (C1 to S2) compression, based on a full spinal MRI or CT scan confirming compression carried out no more than one week prior to treatment
- Single site of compression or multiple sites that can be treated within a single radiation treatment field
- Histologically or cytologically confirmed malignant disease, or for prostate tumours a serum PSA >100 ng/ml at any point prior to randomisation (if biopsy done or planned but results not yet available patients may be entered provided all other inclusion and exclusion criteria are met. Biopsy results must be submitted on the relevant CRF page as soon as they are available)
- Life expectancy >8 weeks
- Age ≥18 years
- Able to give written informed consent
- Willing and able to complete assessment forms

5.3.2 Exclusion criteria

- Patients for whom surgery or chemotherapy treatment is more appropriate
- Patients who are known to be pregnant
- Patients with multiple myeloma, lymphoma, leukaemia or glioma.
- Patients undergoing purely prophylactic treatment in the absence of radiological spinal cord or cauda equina compression
- Patients whose spinal compression site has been treated previously with radiotherapy

5.3.3 Pregnancy and birth control

Due to the risks of radiation damage to an unborn child, women who are known to be pregnant are excluded from the trial. Women who could become pregnant and men who could father a child should be advised of the risks involved, if this is deemed appropriate by the medical team.

A woman of childbearing potential is a sexually mature woman (i.e. any female who has experienced menstrual bleeding) who has not:

- undergone a hysterectomy or bilateral oophorectomy/salpingectomy
- been postmenopausal for 24 consecutive months (i.e. who has had menses at any time in the preceding 24 consecutive months without an alternative medical cause)

6.0 Randomisation procedure

This is a randomised phase III trial comparing single fraction radiotherapy versus multifraction radiotherapy for metastatic spinal cord compression.

Treatment allocation is by randomisation. Patients are stratified by:

1. radiotherapy centre
2. ambulatory status at randomisation
3. type of primary tumour
4. extent of disease (presence or absence of nonskeletal metastases)

Patient randomisation is performed using a 24 hour remote internet based randomisation programme and must be completed prior to commencement of any trial treatment. The programme is hosted and maintained by UCL CTC, and is accessed at:

<https://online.ctc.ucl.ac.uk>

Site staff responsible for the randomisation of patients must register for access to the programme. Details and instructions are provided by UCL CTC.

Following pre-treatment evaluations (as detailed in section 5.1), confirmation of eligibility and consent of a patient at a site, it is recommended that the paper randomisation form is completed fully prior to randomisation. Note that patient initials and date of birth are required for completion of the randomisation programme. Upon randomisation the trial number and treatment allocation are assigned for the patient and these details appear on the randomisation confirmation screen. The trial number and treatment allocation must be recorded in the patient notes. For UK patients, the site must fax the patient contact form (and if used, the randomisation form) to UCL CTC (020 7679 9871) within 48 hours of randomisation. For UK patients, the patient's address and NHS or CHI number must be supplied for the patient contact form. Other than for the purposes of flagging with the Health & Social Care Information Centre, patient name and address is not

stored electronically at UCL CTC. Confirmation of randomisation is sent to the randomiser by email automatically.

6.1 Alternative randomisation procedure for UK sites

During office hours UK sites may also randomise patients into the trial by telephone through UCL CTC on 020 7679 9880. Following pre-treatment evaluations (as detailed in section 5.1), confirmation of eligibility and consent of a patient at a site the randomisation form must be completed fully prior to telephoning UCL CTC. The eligibility criteria are reviewed during the randomisation telephone call using the same form at UCL CTC.

A trial number and treatment allocation are assigned to the patient during the call and must be recorded at site by the caller.

UCL CTC will fax confirmation of the patient's inclusion in the trial, their trial number and treatment allocation to the main site contact. In turn the site must ensure that the randomisation form and patient contact details form are faxed to UCL CTC within 48 hours of randomisation (020 7679 9871). CRFs are available for downloading from the UCL CTC website:

<http://www.ctc.ucl.ac.uk/>

6.2 Alternative randomisation procedure for non-UK sites

If non-UK sites are unable to access the internet randomisation programme they may fax a completed randomisation form to UCL CTC (on +44 (0)20 7769 9871), who will perform the randomisation on their behalf.

Following pre-treatment evaluations (as detailed in section 5.1), confirmation of eligibility and consent of a patient at a site the randomisation form must be fully completed and then faxed to UCL CTC. The faxed randomisation form will be used to confirm patient eligibility by UCL CTC.

A trial number and treatment allocation will be assigned for the patient and details added to the randomisation form, which will then be faxed back to the site.

Please note that if a fax is received outside UCL CTC working hours the randomisation may not be done until the following working day.

Randomisation telephone no.: +44 (0)20 7679 9880

Randomisation fax no.: +44 (0)20 7679 9871

Randomisation programme: <https://online.ctc.ucl.ac.uk/Login.aspx>


**Office hours: 09:00 to 17:00 Monday to Friday
(UK time)**

Once a patient has been randomised onto the trial they must be provided with the following:

- A copy of their signed consent form and patient information sheet
- A patient contact card. Site on call contact details for out of hours medical care must be added to this card and patients advised to carry this with them at all times while participating in the trial.

7.0 Trial treatment

Patients should be treated using MV photon therapy within 48 hours after the decision to treat is made. The decision to treat should be based on a full spinal MRI or CT scan that was performed no more than 7 days prior to treatment.



Arm 1: External beam multifraction radiotherapy: 20Gy/5f

Arm 2: External beam single fraction radiotherapy: 8Gy/1f

NB: Sites can opt out of the multifraction schedule and use their own multifraction schedule in this trial but they must notify UCL CTC of this on the site registration form.

7.1 Treatment planning

The radiotherapy field should be defined on a treatment simulator. Radiotherapy dose should be prescribed at cord depth as measured from the MRI scan or lateral radiograph when simulated.

7.2 Supportive care during treatment

Patients should receive appropriate supportive care as per local practice, which may include:

- Steroids, which should be reduced to the minimum as soon as possible
- Active physiotherapy and rehabilitation to optimise the chances of mobility
- Analgesics and anti-emetics as required

7.3 Management after treatment withdrawal

If the patient withdraws consent or treatment is stopped due to adverse events, subsequent treatment will be at the discretion of the treating clinician.


Refer also to section 13.0 (Withdrawal of patients) for further details regarding treatment discontinuation, patient withdrawal from trial treatment and withdrawal of consent to data collection.

7.4 Post protocol treatment

Post protocol treatment will be at the discretion of the treating clinician.

8.0 Assessments

8.1 Assessments for UK sites



Assessment will comprise:

- a simple 4 point ambulatory scale at weeks 1, 4, 8, and 12 from day 1 of treatment compared to randomisation (see appendix 2.1)
- bladder and bowel function at weeks 1, 4, 8 and 12 from day 1 of treatment compared to randomisation
- assessment of adverse events using the RTOG Acute Radiation Morbidity Scoring Criteria and/or CTCAE v4.02 at weeks 1, 4, 8 and 12 from day 1 of treatment
- Further treatment for primary or SCC
- Preferred and actual places of care
- WHO performance status
- EORTC QLQ-C30 at weeks 1, 4, 8, and 12 from day 1 of treatment compared to randomisation

At 1, 4, 8 and 12 weeks after day 1 of treatment, the site team will contact the patient and collect data on the following:

- ambulatory status
- bladder and bowel function
- adverse events
- WHO performance status
- Further treatment for primary or SCC
- Preferred and actual places of care

The EORTC QLQ-C30 will be posted to the patient, together with a prepaid envelope, for completion at home at 1, 4, 8 and 12 weeks from day 1 of their treatment. In the UK, this will be coordinated from UCL CTC.

If a patient fails to return the questionnaire, UCL CTC will contact the site team at the next follow up timepoint to confirm that there is no reason why the patient has not completed the questionnaire. If the patient agrees to continue completing the QoL questionnaire, this will be posted from UCL CTC.

If the patient is an inpatient at the time of follow up, the site team will be requested to ensure the patient completes the questionnaire.

If the patient is returning home, the site team will ensure that the questionnaire is passed on to the patient at discharge so that the questionnaire can be completed on time.

UCL CTC must be informed if the patient no longer wishes or is unable to complete the questionnaires.

Patients will continue to be followed as standard practice for survival data unless the patient specifically withdraws consent for this.

Where it is known, the patient's ambulatory status must be recorded at the follow up time points unless the patient specifically withdraws consent for this. The data may be collected from a surrogate source i.e. the carers where considered appropriate or the GP or hospital/hospice records if necessary.

8.2 Assessments after completion of first 12 weeks of trial


After the initial twelve weeks' follow up, all efforts must be made by the site to contact the patient's GP or use hospital patient notes to record the patient's ongoing treatments.

- The patient and the patient's carers must not be contacted after the 12 week assessment to gain this information.

At 12 months after first day of treatment, the site must submit details of retreatment (or absence of retreatment) of SCC, together with any further treatment (or absence thereof) to the primary cancer or other metastases on the appropriate form.

Sites must return the death form at 12 months as well, to record whether or not the patient remains alive at this timepoint.

8.3 Assessments for non-UK sites



Assessment will comprise:

- a simple 4 point ambulatory scale at weeks 1, 4, 8, and 12 from day 1 of treatment compared to randomisation (see appendix 2.1)
- bladder and bowel function at weeks 1, 4, 8 and 12 from day 1 of treatment compared to randomisation
- assessment of adverse events using the RTOG Acute Radiation Morbidity Scoring Criteria and/or CTCAE v4.02 at weeks 1, 4, 8 and 12 from day 1 of treatment
- Further treatment for primary or SCC
- Preferred and actual places of care
- WHO performance status
- EORTC QLQ-C30 at weeks 1, 4, 8, and 12 from day 1 of treatment compared to randomisation

For non-UK sites with a Country Coordinating Centre (CCC) it will be the responsibility of the CCC to coordinate the collection of trial data at each of the assessment timepoints.

Where there is no CCC in the country, sites must submit data to UCL CTC at each of the assessment timepoints.

At 1, 4, 8 and 12 weeks after day 1 of treatment, the site should contact the patient and collect data on the following:

- ambulatory status
- bladder and bowel function
- adverse events
- WHO performance status
- Further treatment for primary or SCC
- Preferred and actual places of care

Patients should also complete the EORTC QLQ-C30 quality of life questionnaire at each of these timepoints. The administration and collection of this should be performed according to local site procedures. Detailed instructions for assessments, administration of questionnaires and collection of data will be provided in the ISF.

9.0 Data management and data handling guidelines

Data will be collected from sites on version controlled case report forms (CRFs) designed for the trial and supplied by UCL CTC. Data entered on CRFs must be verifiable from source data at site. Source data are contained in source documents and must be accurately transcribed on to the CRF. Examples of source documents are hospital records which include clinical reports.

Where copies of supporting source documentation are being submitted to UCL CTC, the patient's trial number must be clearly indicated on all material and any patient identifiers removed or blacked out prior to sending to maintain confidentiality.

Please note that, for this trial, UK patients have consented to their names and addresses being supplied to UCL CTC. This is:

- for flagging with the Health & Social Care Information Centre
- in order to send QoL forms directly to patients

9.1 Completing case report forms

All CRFs must be completed and signed by staff who are listed on the site staff delegation log and authorised by the PI to perform this duty. The PI is responsible for the accuracy of all data reported in the CRF.

All entries must be clear, legible and written in ball point pen. Any corrections made to a CRF at site must be made by drawing a single line through the incorrect item ensuring that the previous entry is not obscured. Each correction must be dated and initialled. Correction fluid must not be used. The use of abbreviations and acronyms must be avoided. Once completed the original CRFs must be sent to UCL CTC (or via the CCC for non-UK sites) and a copy kept at site.

9.2 Missing data

To avoid the need for unnecessary data queries CRFs must be checked at site (and CCC if applicable) to ensure there are no blank fields before sending to UCL CTC.

- When data are unavailable because a measure has not been taken or test not performed, enter "ND" for not done.
- If an item was not required at the particular time the form relates to, enter "NA" for not applicable.
- When data are unknown enter the value "NK" (only use if every effort has been made to obtain the data).

9.3 Timelines for data return

For UK sites, the randomisation (if randomisation was via phone) and patient contact forms must be faxed to UCL CTC within 48 hours of a patient being randomised, to allow forwarding of the week 1 Quality of Life questionnaire to the patient in good time.

UK sites must complete and submit the entry and treatment forms within one week of the patient being seen.

For UK sites all other forms must be completed and submitted within two weeks of the patient being assessed.

Non-UK sites with a CCC must complete and submit the randomisation form within 48 hours of randomisation to their CCC. The entry and treatment forms must be submitted to their CCC within one week of the patient being seen. All other forms must be completed and submitted to the CCC within two weeks of the patient being assessed. CCCs must forward all CRFs to UCL CTC within five business days of receipt.

Non-UK sites without a CCC must complete and submit all CRFs to UCL CTC within two weeks of the patient being assessed.

9.3.1 Timelines for CRF submissions (UK sites):

Form	Submission time limit (from date of event)
Randomisation form	By fax, within 48 hours (phone based randomisations only)
Patient Contact form	By fax, within 48 hours
Entry form	1 week
Medical history form	1 week
Treatment form (both arms)	1 week
Follow up forms	2 weeks
Adverse event forms	2 weeks
Quality of life forms	2 weeks (if inpatient)
Off study form	2 weeks
Retreatment form	2 weeks of becoming aware of event and at 12 months after randomisation
Primary cancer therapy form	2 weeks of becoming aware of event and at 12 months after randomisation
Serious adverse event report form	24 hours of becoming aware of event
Death form	2 weeks of becoming aware of event or at 12 months after randomisation, if patient is still alive

Sites who persistently do not return data within the required timelines may be suspended from recruiting further patients into the trial by UCL CTC and subjected to a 'for cause' monitoring visit. See section 12.2 ('For cause' on site monitoring) for details.

9.4 Data queries

Data arriving at UCL CTC will be checked for legibility, completeness, accuracy and consistency, including checks for missing or unusual values. Query reports will be sent to the data contact at site (or CCC where applicable). Further guidance on how data contacts should respond to data queries can be found in the query reports.

10.0 Safety reporting

10.1 Definitions of Adverse Events

The following definitions have been adapted from Directive 2001/20/EC, ICH E2A “Clinical Safety Data Management: Definitions and Standards for Expedited Reporting” and ICH GCP E6:

Adverse Event (AE)

Any untoward medical occurrence or effect in a patient treated on a trial protocol, which does not necessarily have a causal relationship with a trial treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a trial treatment, whether or not related to that trial treatment.

Adverse Reaction (AR)

All untoward and unintended responses to a trial treatment related to any dose administered. A causal relationship between the trial treatment and an adverse event is at least a reasonable possibility, i.e. the relationship cannot be ruled out.

Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR)

An adverse event or adverse reaction that at any dose:

- Results in death
- Is life threatening (the term “life threatening” refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event that hypothetically might have caused death if it were more severe)
- Requires inpatient hospitalisation or prolongs existing hospitalisation
- Results in persistent or significant disability/incapacity
- Is a congenital anomaly or birth defect
- Is otherwise medically significant (e.g. important medical events that may not be immediately life threatening or result in death or hospitalisation but may jeopardise the patient or may require intervention to prevent one of the other outcomes listed above)

Suspected Unexpected Serious Adverse Reaction (SUSAR)

A serious adverse reaction, the nature or severity of which **is not consistent** with the applicable trial treatment information.

10.2 Reporting procedures

10.2.1 All Adverse Events (AEs)

All adverse events that occur between informed consent and 12 weeks post randomisation must be recorded in the patient notes and the trial CRFs. Those meeting the definition of a Serious Adverse Event (SAE) must also be reported to UCL CTC using the trial specific SAE Report. Also refer to section 10.2.2 (Serious Adverse Events (SAEs)).

Pre-existing conditions do not qualify as adverse events unless they worsen. These however should be recorded on the Medical History Form in the CRFs.

Overdoses

All accidental or intentional overdoses, whether or not they result in adverse events, must be recorded in the patient notes and CRFs. Overdoses resulting in an adverse event are classified as SAEs and must be reported to UCL CTC according to SAE reporting procedures. The fact that an overdose has occurred must be clearly stated on the SAE Report. Also refer to section 10.2.2 (Serious Adverse Events (SAEs)).

Sites must inform UCL CTC immediately when an overdose has been identified. Also refer to section 11.0 (Incident reporting).

Adverse Event term

An adverse event term must be provided for each adverse event, preferably using the term listed in the RTOG Acute Radiation Morbidity Scoring Criteria or Common Terminology Criteria for Adverse Events (CTCAE) v4.02 available online at:

<http://www.rtog.org/ResearchAssociates/AdverseEventReporting/AcuteRadiationMorbidityScoringCriteria.aspx>

http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf

Severity

Severity of each adverse event must be determined by using the RTOG Acute Radiation Morbidity Scoring Criteria and CTCAE v4.02 as a guideline, wherever possible. These criteria are available online at:

<http://www.rtog.org/ResearchAssociates/AdverseEventReporting/AcuteRadiationMorbidityScoringCriteria.aspx>

http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf

In those cases where the RTOG Acute Radiation Morbidity Scoring Criteria or CTCAE v4.02 do not apply, severity should be coded according to the following criteria:

1 = Mild	(awareness of a sign or symptom, but easily tolerated)
2 = Moderate	(discomfort enough to cause interference with normal daily activities)
3 = Severe	(inability to perform normal daily activities)
4 = Life threatening	(immediate risk of death from the reaction as it occurred)
5 = Fatal	(the event resulted in death)

Causality

The PI, or other delegated site investigator, must perform an evaluation of causality for each adverse event.

Causal relationship to each trial treatment must be determined as follows:

- **None**
There is no evidence of any causal relationship.
- **Unlikely**
There is little evidence to suggest a causal relationship (e.g. because the event did not occur within a reasonable time after administration of a trial treatment). There is another reasonable explanation of the event (e.g. the patient's clinical condition, other concomitant treatments).
- **Possibly**
There is some evidence to suggest a causal relationship (e.g. because the event occurs within a reasonable time after administration of a trial treatment). However, the influence of other factors may have contributed to the event (e.g. the patient's clinical condition, other concomitant treatments).
- **Probably**
There is evidence to suggest a causal relationship and the influence of other factors is unlikely.
- **Definitely**
There is clear evidence to suggest a causal relationship and other possible contributing factors can be ruled out.

UCL CTC will consider events evaluated as possibly, probably or definitely related to be adverse reactions.

10.2.2 Serious Adverse Events (SAEs)

All SAEs that occur between informed consent and 12 weeks post randomisation (or after this date if the site investigator feels the event is related to the trial treatment) must be submitted to UCL CTC by fax within **24 hours** of observing or learning of the event, using the trial specific SAE Report. All sections on the SAE Report must be completed. If the event is **not being reported within 24 hours** to UCL CTC, the circumstances that led to this must be detailed in the SAE Report to avoid unnecessary queries.

Exemptions from SAE Report Submission


For this trial, the following events are exempt from requiring submission on an SAE Report, but must be recorded in the relevant section(s) of the trial CRFs:

- events that occur after 12 weeks post randomisation that are not considered to be side effects of the trial treatment
- disease progression (including disease related deaths)

**Please note that hospitalisation for elective treatment
or palliative care does not qualify as an SAE.**

**Completed SAE Reports must be faxed
within 24 hours of becoming aware
of the event to UCL CTC**

Fax: +44 (0)20 7679 9871

Adverse Event reporting flowchart

SAE follow up reports

All SAEs must be followed up until resolution and until there are no further queries. The PI, or other delegated site investigator, must provide follow up SAE Reports if the SAE had not resolved at the time the initial report was submitted.

SAE processing at UCL CTC

On receipt of the SAE Report, UCL CTC will check for legibility, completeness, accuracy and consistency. Expectedness will be evaluated, to determine whether or not the case qualifies for expedited reporting, using the list of expected adverse events for radiotherapy to the spine in protocol appendix 3.

The CI, or their delegate (e.g. a clinical member of the TMG), may be contacted to review the SAE and to perform an evaluation of causality on behalf of UCL CTC. If UCL CTC has considered expectedness difficult to determine, the CI, or their delegate, will be consulted for their opinion at this time.

10.3 SUSARs

If the event is evaluated as a Suspected Unexpected Serious Adverse Reaction (SUSAR), UCL CTC will submit a report to the UK REC within 15 calendar days and to CCCs/CLs for forwarding to their ethics committee(s) within the timeframe required in that country. UCL CTC will ensure that consideration is given where the reporting deadline occurs at a weekend to allow reporting within the required timeframe. Where there are conflicting evaluations of causal relationship by the site and UCL CTC/CI, both opinions will be reported.

Informing sites of SUSARs

UCL CTC will inform all UK PIs of any SUSARs that occur on the trial. PIs will receive a quarterly line listing which must be processed according to local requirements. For participating countries outside the UK, UCL CTC will submit reports to CCCs for forwarding to the PIs in their country within one business day. Where there is no CCC, UCL CTC will submit SUSAR reports directly to sites in that country.

10.4 Safety monitoring

UCL CTC will provide safety information to the TMG and the IDMC on a periodic basis for review.

Trial safety data will be monitored to identify:

- new adverse reactions to the trial treatment regimen or any trial treatment;
- trial related events that are not considered related to the trial treatment regimen.

Should UCL CTC identify or suspect any issues concerning patient safety at any point throughout the trial, the CI or TMG will be consulted for their opinion.

10.5 Pregnancy

If a female patient or the female partner of a male patient becomes pregnant at any point during the trial, a completed trial specific Pregnancy Report must be submitted to UCL CTC by fax within **24 hours** of learning of its occurrence. Consent to report information regarding the pregnancy must be obtained from the pregnant patient/partner. The trial specific pregnancy monitoring information sheets and informed consent forms for trial patients and the partners of trial patients must be used for this purpose.

All pregnancies must be reported by faxing a completed
Pregnancy Report within **24 hours** of becoming aware of the
pregnancy to UCL CTC
Fax: +44 (0) 20 7679 9871

Pregnancy follow up reports

All pregnancies must be followed up until an outcome is determined. Follow up Pregnancy Reports must be submitted to UCL CTC by fax within **24 hours** of learning of the outcome. Reports must include an evaluation of the possible relationship of the trial treatment to the pregnancy outcome.

SAEs during pregnancy

Any SAE occurring in a pregnant patient must be reported using the trial specific SAE Report, according to SAE reporting procedures. Refer to section 10.2.2 (Serious Adverse Events (SAEs)) for details.

Pregnancy Report processing at the UCL CTC

The UCL CTC will submit a Report to the UK REC, CCCs and CLSs should the pregnancy outcome meet the definition of a SUSAR. Refer to section 10.3 (SUSARs) for details.

11.0 Incident reporting

Organisations must notify UCL CTC of all deviations from the protocol or Good Clinical Practice (GCP) immediately. UCL CTC may require a report on the incident(s) and a form will be provided if the organisation does not have an appropriate document (e.g. Trust Incident Form for UK sites).

If site staff are unsure whether a certain occurrence constitutes a deviation from the protocol or GCP, the UCL CTC trial team can be contacted immediately to discuss.

Where the incident has occurred in a site outside the UK, the CCC/CLS in that country must also notify the relevant ethics committee according to local requirements. Where UCL CTC identifies an incident at a site outside the UK, the CCC/CLS in the country where the incident occurred will be informed.

UCL CTC will use an organisation's history of non compliance to make decisions on future collaborations.

12.0 Trial monitoring and oversight

UK participating sites and PIs must agree to allow trial related on site monitoring, Sponsor audits and regulatory inspections by providing direct access to source data/documents as required. Patients are informed of this in the patient information sheet and are asked to consent to their medical notes being reviewed by appropriate individuals on the consent form.

UCL CTC will determine the appropriate level and nature of monitoring required for the trial. Risk will be assessed on an ongoing basis and adjustments made accordingly.

In addition, monitoring of non UK sites will be performed in accordance with the regulatory requirements of each country.

12.1 Central monitoring

All Sites will be required to submit screening logs and staff delegation logs to the UCL CTC (or their CCC) at the frequency detailed in the trial monitoring plan or on request and these will be checked for consistency and completeness. Also refer to sections 3.2.2 (Required documentation) and 5.2 (Screening log).

In the UK a copy of the consent form for each patient must also be submitted to UCL CTC. These will be checked for completeness and accuracy i.e. the correct version of the form has been used, patient initials in every box, patient name and signature on the form, patient personally completed date of signing and the person taking consent has signed and dated and is listed on the delegation log as authorised to perform this duty. Also refer to section 4.0 (Informed consent).

Non-UK sites will be required to maintain a log of all patient informed consent forms that have been completed at site (regardless of whether the patient is subsequently randomised to the trial). This log will include details of the versions of informed consent form/patient information sheet used, patient completion of the consent form, date of consent, the name of the person taking consent, etc. A

copy of the ICF log must be submitted to UCL CTC at the frequency detailed in the trial monitoring plan or on request. Also refer to section 4.0 (Informed consent).

Sites will be requested to conduct quality control checks of documentation held within their Investigator Site Files at the frequency detailed in the trial monitoring plan. Checklists detailing the current version and date of version controlled documents will be provided for this purpose.

UK patients enrolled onto SCORAD III will be flagged with the Health & Social Care Information Centre.

Data received at UCL CTC will be subject to review in accordance with section 9.4 (Data queries).

Where central monitoring of data and/or documentation submitted by sites indicates that a patient may have been placed at risk, the matter will be raised urgently with site staff and escalated as appropriate (refer to sections 11.0 Incident reporting and 12.2 'For cause' on site monitoring for further details).

12.2 'For cause' on site monitoring

On site monitoring visits may be scheduled at a site where there is evidence or suspicion of non compliance with important aspect(s) of the trial protocol/GCP requirements. Sites will be sent a letter in advance outlining the reason(s) for the visit. The letter will include a list of the documents that are to be reviewed, interviews that will be conducted, planned inspections of the facilities, who will be performing the visit and when the visit is likely to occur.

Following a monitoring visit, the trial monitor/trial coordinator will provide a report to the site, which will summarise the documents reviewed and a statement of findings, deviations, deficiencies, conclusions, actions taken and actions required. The PI at each site will be responsible for ensuring that monitoring findings are addressed (this may be delegated to an appropriate member of staff).

UCL CTC will assess whether it is appropriate for the site to continue participation in the trial. Refer to section 11.0 (Incident reporting) for details.

12.3 Oversight Committees

12.3.1 Trial Management Group (TMG)

The Trial Management Group (TMG) will include the Chief Investigator, clinicians and experts from relevant specialities and SCORAD III trial staff from UCL CTC (see page 3). The TMG will be responsible for overseeing the trial. The group will meet regularly and will send updates to PIs (via newsletters) and to the meetings of the national working groups as requested.

The TMG will review substantial amendments to the protocol prior to submission to the REC. All PIs will be kept informed of substantial amendments through their nominated responsible individuals.

All members of the TMG must sign the SCORAD III TMG charter and supply this to the SCORAD III trial coordinator at, or prior to, their first meeting.

12.3.2 Trial Steering Committee (TSC)

The role of the TSC is to provide overall supervision of the trial. The TSC will review the recommendations of the IDMC and, on consideration of this information, recommend any appropriate amendments/actions for the trial as necessary. The TSC acts on behalf of the funder and Sponsor.

A TSC charter will summarise the roles and responsibilities of the TSC and each member will be required to sign this prior to the first meeting.

12.3.3 Independent Data Monitoring Committee (IDMC)

The role of the IDMC is to provide independent advice on data and safety aspects of the trial. Meetings of the Committee will be held periodically, or as necessary to

address any issues. The IDMC is advisory to the TSC and can recommend premature closure of the trial to the TSC.

An IDMC charter will summarise the roles and responsibilities of the IDMC and each member will be required to sign this prior to the first meeting.

12.4 Role of UCL CTC

UCL CTC will be responsible for the day to day coordination and management of the trial and will act as custodian of the data generated in the trial (on behalf of UCL). UCL CTC is responsible for all duties relating to safety reporting which are conducted in accordance with section 10.0 (Safety reporting).

13.0 Withdrawal of patients

In consenting to the trial, patients are consenting to trial treatment, assessments, follow up and data collection.

Discontinuation of trial treatment for clinical reasons

A patient may be withdrawn from trial treatment whenever continued participation is no longer in the patient's best interests, but the reasons for doing so must be recorded. Reasons for discontinuing treatment may include:

- Disease progression whilst on therapy
- Unacceptable toxicity
- Intercurrent illness which prevents further treatment
- Patients withdrawing from further trial treatment
- Any alteration in the patient's condition which justifies the discontinuation of treatment in the site investigator's opinion

In these cases patients remain within the trial for the purposes of follow up and data analysis according to the treatment option to which they have been allocated.

Patient withdrawal from trial treatment

If a patient expresses their wish to withdraw from trial treatment, sites should explain the importance of remaining on trial follow up, or failing this of allowing routine follow up data to be used for trial purposes and for allowing existing collected data to be used. If a patient gives a reason for their withdrawal, this must be recorded.

Withdrawal of consent to data collection

If a patient **explicitly** states they do not wish not to contribute further data to the trial, their decision must be respected and recorded on the Off study form in the CRF booklet. In this event details must be recorded in the patient's hospital records, no further CRFs must be completed and no further data sent to UCL CTC (or CCC for non-UK sites).

Losses to follow up

If a patient moves from the area, every effort must be made for the patient to be followed up at another participating trial site and for this new site to take over the responsibility for the patient, or for follow up via the GP. Details of participating trial sites can be obtained from the UCL CTC trial team who must be informed of the transfer of care and follow up arrangements.

If a patient is lost to follow up at a site every effort must be made to contact the patient's GP to obtain information on the patient's status.

UK patients who are lost to follow up will be tracked by UCL CTC via the Health & Social Care Information Centre.

14.0 Trial closure

14.1 End of trial

For regulatory purposes the end of the trial will be 12 months after randomisation of the last patient or the death of the last surviving patient, whichever event occurs first. At this point the 'declaration of end of trial' form will be submitted to the ethics committee, as required.

Following this, UCL CTC will advise sites on the procedure for closing the trial at the site.

14.2 Archiving of trial documentation

At the end of the trial, UCL CTC will archive securely all centrally held trial related documentation for a minimum of 5 years. Arrangements for confidential destruction will then be made. It is the responsibility of PIs to ensure data and all essential documents relating to the trial are held at site for a minimum of 5 years after the end of the trial, in accordance with national legislation and for the maximum period of time permitted by the site.

Essential documents are those which enable both the conduct of the trial and the quality of the data produced to be evaluated and show whether the site complied with the principles of GCP and all applicable regulatory requirements.

UCL CTC will notify sites when trial documentation held at sites may be archived. All archived documents must continue to be available for inspection by appropriate authorities upon request.

14.3 Early discontinuation of trial

The trial may be stopped before completion as an Urgent Safety Measure on the recommendation of the TSC or IDMC (refer to sections 12.3.2 Trial Steering Committee (TSC) and 12.3.3 Independent Data Monitoring Committee (IDMC)). Sites will be informed in writing by UCL CTC of reasons for early closure and the actions to be taken with regard to the treatment and follow up of patients.

14.4 Withdrawal from trial participation by a site

Should a site choose to close to recruitment the PI must inform UCL CTC in writing. Follow up as per protocol must continue for all patients recruited into the trial at that site and other responsibilities continue as per the CTSA.

15.0 Statistics

This is a non-inferiority trial to show that ambulatory status using 8Gy in 1 fraction is no worse than 20Gy in 5 fractions.

15.1 Proposed sample size

Using the data from patients recruited to the feasibility stage of SCORAD, the percentage of patients with a response was about 75%. A maximum allowable difference of 11 percentage points is specified, i.e. using 8Gy in 1 fraction should not have a true response rate lower than 64% (or the true difference between the proportion of patients who respond should not exceed -11%). A non-inferiority trial would need 386 patients (193 per group), with 80% power and one-sided 5% level of statistical significance)²⁴. About 33% of patients die before the 8 week assessment, so allowing for this increases **the target sample size to 580 patients**. This will be the minimum target.

To allow for the possibility of a lower response rate of 65% (instead of 75%) would require a sample size of 464 patients, or 700 allowing for the 33% death rate. The IDMC will monitor the response rate and make recommendations on continuing recruitment past N=580, considering other factors such as feasibility and funding.

15.2 Planned analyses

At 8 weeks the response rate (i.e. those with no change in ambulatory status 1 to 2 from randomisation, or improvement) will be compared using a chi-squared test. The risk difference (and 95% confidence interval) will be obtained.

Other categorical endpoints will be analysed in a similar way, e.g. ambulatory status at 1, 4 and 12 weeks (where available), and bladder and bowel function. Where endpoints have multiple timepoints, the p value could be inflated to allow for this.

Duration of care in home, hospital, hospice or nursing home will be compared using the Wilcoxon test, and the median days estimated in each trial group.

Survival will be examined using Kaplan-Meier plots, and compared between the two treatment groups using the hazard ratio and logrank test.

Quality of life will be examined using a repeated measures analysis (e.g. mixed model).

15.3 Subgroup analyses

The difference in response rate between the two groups will be examined according to

- age
- ambulatory status at randomisation
- primary tumour type
- extent of metastases (presence or absence of nonskeletal metastases)

A formal test for interaction will be used for each of these four factors.

15.4 Interim analyses of efficacy

No formal interim analyses of efficacy are planned. These will be carried out if the Independent Data Monitoring Committee request this as part of their assessment of the trial.

15.5 Quality of life assessments

Assuming that quality of life measures are Normally distributed (which they reasonably are, on either the original or logarithmic scale), a trial of 400 patients, after allowing for a 33% death rate by 8 weeks (see section 15.1), would be enough to detect a reasonably small/moderate maximum allowable difference of 0.28 standard deviation units (assuming non-inferiority, 80% power and one-sided 2.5% level of statistical significance).

16.0 Ethical approvals

In conducting the Trial the Sponsor, UCL CTC and sites shall comply with all laws and statutes, as amended from time to time, applicable to the performance of clinical trials including, but not limited to:

- the principles of ICH Harmonised Tripartite Guideline for Good Clinical Practice
- the Human Rights Act 1998
- the Data Protection Act 1998
- the Freedom of Information Act 2000
- the Mental Capacity Act 2005
- the Research Governance Framework for Health and Social Care, issued by the UK Department of Health (Second Edition 2005) or the Scottish Health Department Research Governance Framework for Health and Community Care (Second Edition 2006)

All non-UK sites must comply with all their local laws and statutes applicable to the performance of clinical trials.

16.1 Ethical approval

The trial will be conducted in accordance with the World Medical Association Declaration of Helsinki entitled 'Ethical Principles for Medical Research Involving Human Subjects' (1996 version) and in accordance with the terms and conditions of the ethical approval given to the trial.

The trial has received a favourable opinion from the London – Camden & Islington Research Ethics Committee (formerly North West London REC 1 and Camden & Islington Community REC).

UCL CTC will submit Annual Progress Reports to the REC annually on the anniversary of the date of ethical approval for the trial.

16.2 Site approvals

Evidence of approval from the Trust R&D for a trial site must be provided to UCL CTC. Sites will only be activated when all necessary local approvals for the trial have been obtained.

All non-UK sites must provide confirmation of approval of their local institution(s).

16.3 Protocol amendments

UCL CTC will be responsible for gaining ethical approval for amendments made to the protocol and other trial related documents. Once approved, UCL CTC will ensure that all amended documents are distributed to sites, CLRN and CCCs/CLSs as appropriate.

In the UK site staff will be responsible for acknowledging receipt of documents and for implementing all amendments.

Non-UK sites will be responsible for gaining approvals according to their local procedures, and for providing UCL CTC with evidence of this.

16.4 Patient confidentiality and data protection

For UK sites patient identifiable data, including full name, address, date of birth and NHS or CHI number will be required for the randomisation process and will be provided to UCL CTC. UCL CTC will preserve patient confidentiality and will not disclose or reproduce any information by which patients could be identified, other than to the Health & Social Care Information Centre for flagging purposes. Data will be stored in a secure manner and UCL CTC trials are registered in accordance with the Data Protection Act 1998 with the Data Protection Officer at UCL.

CCCs will be responsible for registering the trial with their data protection agency if required for that country and for ensuring that each site complies with Local Data Protection Legislation and takes appropriate measures against unauthorised or unlawful processing of personal data and against accidental loss or destruction of, or damage to personal data.

Non-UK sites without a CCC will be responsible for ensuring that Local Data Protection Legislation is complied with and for taking appropriate measures against unauthorised or unlawful processing of personal data and against accidental loss or destruction of, or damage to personal data.

17.0 Sponsorship and Indemnity

Sponsor Name: University College London

Address: **Joint Research Office**

Gower Street
London
WC1E 6BT

Contact: Director of Research Support

Tel: +44 (0) 20 3447 9995/2178 (unit admin)

Fax: +44 (0) 20 3447 9937

17.1 Indemnity

University College London holds insurance to cover participants for injury caused by their participation in the clinical trial. Participants may be able to claim compensation if they can prove that UCL has been negligent. However, as this clinical trial is being carried out in a hospital, the hospital continues to have a duty of care to the participant of the clinical trial. University College London does not accept liability for any breach in the hospital's duty of care, or any negligence on the part of hospital employees. This applies whether the hospital is an NHS Trust or not. This does not affect the participant's right to seek compensation via the non-negligence route.

Participants may also be able to claim compensation for injury caused by participation in this clinical trial without the need to prove negligence on the part of University College London or another party. Participants who sustain injury and wishing to make a claim for compensation should do so in writing in the first instance to the Chief Investigator who will pass the claim to the Sponsor's Insurers, via the Sponsor's office.

Hospitals selected to participate in this clinical trial shall provide clinical negligence insurance cover for harm caused by their employees and a copy of the relevant insurance policy or summary shall be provided to University College London, upon request.

18.0 Funding

Cancer Research UK is supporting the central coordination of the trial through UCL CTC.

19.0 Publication policy

All publications and presentations relating to the trial must be authorised by the TMG. The first publication of the trial results will be in the name of the TMG, if this does not conflict with the journal's policy. The TMG will form the basis of the writing committee and advise on the nature of publications. If there are named authors, these should include the Chief Investigator, Trial Coordinators and Statisticians involved in the trial. Contributing site investigators in this trial will also be acknowledged. Data from all sites will be analysed together and published as soon as possible. Participating sites must not publish trial results prior to the first publication by the TMG or without prior written consent from the TMG. The trial data is owned by UCL CTC. The ISRCTN number (ISRCTN97108008) allocated to this trial must be quoted in any publications resulting from this trial.

20.0 References

1. Ushio Y, Posner R, Posner JB et al. Experimental spinal cord compression by epidural neoplasm. *Neurology* 1977; **27**: 422-429.
2. Patchell R, Tibbs PA, Regine WF et al. A randomised trial of direct decompressive surgical resection in the treatment of spinal cord compression caused by metastasis. *Proc ASCO* 2003 Abs 2.
3. Makris A, Kunkler I. The Barthel Index in assessing the response to palliative radiotherapy in malignant spinal cord compression: a prospective audit. *Clinical Oncology* 1995; **7**: 82-86.
4. Rades D, Fehlaue F, Hartmann A, Wildfang I, Karstens J4 and Alberti W. Reducing the Overall Treatment Time for Radiotherapy of Metastatic Spinal Cord Compression (MSCC): 3-Year Results of a Prospective Observational Multi-Center Study. *Journal of Neuro-Oncology* 2004; **70** (1): 77-82.
5. Maranzano E, Bellavita R, Rossi R, De Angelis V, Fratteggianni A, Bagnoli R, Mignogna M, Beneventi S, Lupattelli M, Ponticelli P, Biti GP and Latini P. Short-Course Versus Split-Course Radiotherapy in Metastatic Spinal Cord Compression: Results of a Phase III, Randomized, Multicenter Trial. *Journal of Clinical Oncology* 2005; **23** (15): 3358-3365.
6. Deacon J, Peckham MJ and Steel GG. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. *Radiotherapy and Oncology* 1984; **2**: 317-323.
7. Price P, Hoskin PJ, Easton D et al. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. *Radiotherapy and Oncology* 1986; **6**: 247 – 255.
8. MRC Lung Cancer Working Party. Inoperable NSCLC: A Medical research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. *British Journal of Cancer* 1991; **63**: 265 – 270.
9. Priestman TJ, Dunn J, Brada M et al. Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. *Clinical Oncology* 1996; **8**: 308-315.
10. Makin WP. Management of spinal cord compression due to metastatic cancer. First International Consensus Workshop on Radiation Therapy in the Treatment of Metastatic and Locally Advanced Disease (1990) *Washington Abstract* 3A-7.
11. Jeremic B, Djuric L, Mijatovic L. Role of radiotherapy in metastatic spinal cord compression. First International Consensus Workshop on Radiation Therapy in the Treatment of Metastatic and Locally Advanced Disease (1990) *Washington Abstract* 3A-8.
12. Hoskin PJ, Grover A, Bhana R. Metastatic spinal cord compression: radiotherapy outcome and dose fractionation. *Radiotherapy and Oncology* 2003; **68**: 175-180.
13. Findlay GFG. Adverse effects of the management of spinal cord compression. *J Neurol Neurosurg Psychiatry* 1984; **47**: 139-144.
14. Rades D, Stalpers L, Hulshof M, Zschenker O, Alberti W, Koning C. Effectiveness and toxicity of single-fraction radiotherapy with 1x8Gy for metastatic spinal cord compression. *Radiotherapy and Oncology* 2005; **76** (1): 70-73.
15. Rades D, Stalpers L, Hulshof M, Borgmann K, Karstens J, Koning C and Alberti W. Comparison of 1 x 8 Gy and 10 x 3 Gy for functional outcome in patients with metastatic spinal cord compression. *Int. J. Radiation Oncology Biol. Phys.* 2005; **62** (2): 514-518.
16. Rades D, Stalpers L, Veninga T, Schulte R, Hoskin PJ, Obralic N, Bajrovic A, Rudat V, Schwarz R, Hulshof MC, Poortmans P, Schild SE. Evaluation of Five Radiation Schedules and Prognostic Factors for Metastatic Spinal Cord Compression. *Journal of Clinical Oncology* 2005; **23** (15): 3366-3375.

17. Trippa F, Maranzano E, Rossi R et al. Phase III randomised clinical trial of two different hypofractionated radiotherapy schedules (8Gy x 2 vs 8Gy) in metastatic spinal cord compression. An Interim analysis. *Radiotherapy and Oncology* 2004; **73** (Suppl 1): S207.
18. UK NICE guidelines on metastatic spinal cord compression. November 2008
19. Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence based guideline. *JCO* 1998; **16**: 1613
20. Loblaw DA, Perry J, Chambers A and Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the cancer care Ontario practice guidelines initiatives neuro-oncology disease site group. *JCO* 2005 **23** (9): 2028
21. George R et al. Interventions for the treatment of metastatic extradural spinal cord compression in adults (Review). *The Cochrane Collaboration* 2008
22. Maranzano E, Bellavita R, Floridi P, Celani G, Righetti E, Lupatelli M et al. Radiation induced myelopathy in long-term surviving metastatic spinal cord compression patients after hypofractionated radiotherapy: a clinical and magnetic resonance imaging analysis. *Radiotherapy and Oncology* 2001; **60**: 281-288.
23. Macbeth FR, Wheldon TE, Girling DJ, et al: Radiation myelopathy: Estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. The Medical Research Council Lung Cancer Working Party. *Clinical Oncology* (Royal College of Radiologists) 1996; **8**:176-181.
24. Machin et al. Sample size tables for clinical studies. Second Edition. Blackwell Science 1997
25. Neal AJ, Hoskin PJ. (Eds): *Clinical Oncology Basic Principles and Practice*, 4E. Hodder Arnold 2009: 48-49
26. Hoskin P. (Ed.) *Radiotherapy in Practice External beam Therapy*. OUP, 2006

Appendix 1: Abbreviations

#	Fraction (radiotherapy dosage)
AE	Adverse Event
AR	Adverse Reaction
CCC	Country Coordinating Centre
CI	Chief Investigator
CLS	Country Lead Site
CRF	Case Report Form
CT	Computerised Tomography
CTAAC	Clinical Trials Advisory & Awards Committee
CTCAE	National Cancer Institute Common Terminology Criteria for Adverse Events
CTRad	the NCRI Clinical and Translational Radiotherapy Research Working Group
DPA	Data Protection Act
EORTC QLQ-C30	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 – item core quality of life questionnaire
GCP	ICH Harmonised Tripartite Guideline for Good Clinical Practice
Gy	Gray, SI unit for radiation dosage, energy absorbed per unit mass (joules/kg).
Gy/f or Gy/#	Grays per fraction
f	Fraction (radiotherapy dosage)
ICH GCP	International Conference of Harmonisation-Good Clinical Practice
ICRP	International Cancer Research Portfolio
ICTSA	International Clinical Trials Site Agreement
IDMC	Independent Data Monitoring Committee
IRAS	Integrated Research Application System
ISF	Investigator site file
ISRCTN	International Standard Randomised Controlled Trial Number
MRC CTU	Medical Research Council Clinical Trials Unit
MRI	Magnetic resonance imaging
MSCC	Metastatic spinal cord compression
NCRI	National Cancer Research Institute
NCRN	National Cancer Research Network
NHS	UK National Health Service
NICE	National Institute for Clinical Excellence
NIHR	UK National Institute for Health Research
ng/mL	Nanogram per millilitre
NRES	National Research Ethics Service
OS	Overall Survival
PI	Principal Investigator
PSA	Prostate specific antigen
Pt	Patient
QoL	Quality of life
R&D	Research and development
RCT	Randomised controlled trial
REC	Research Ethics Committee
RTOG	Radiation Therapy Oncology Group
SAE	Serious Adverse Event
SF2	Single fraction of 2Gy
SSI	Site Specific Information
SCC	Spinal Cord Compression
SUSAR	Suspected Unexpected Serious Adverse Reaction
TMF	Trial Master File
TMG	Trial Management Group
TSC	Trial Steering Committee
UCL	University College London
UCL CTC	CR UK and UCL Cancer Trials Centre

Appendix 2: Definition of secondary endpoints

Ambulatory status definitions:

Neurologic assessment will be performed and categorised as:

Category	Definition
1	Ambulatory without the use of walking aids and grade 5/5 power in all muscle groups
2	Ambulatory with assistance of walking aids or grade 4/5 power in any muscle group
3	Unable to ambulate with no worse than grade 2/5 power in all muscle groups; or grade 2/5 power in any muscle group
4	Absence (0/5) or flicker (1/5) of motor power in any muscle group

1. Ambulatory status:

- **Recovery of and time to ambulation:** Recovery of ambulation is defined as the movement from either Grade 3 or 4 at randomisation to either Grade 1 or Grade 2 at subsequent time points.
 - A change from Grade 2 to Grade 1 must also be reported.
- **Maintenance of ambulatory status:** This is defined as the maintenance of an ambulatory score of Grade 1 or 2.

2. Bladder function:

- Dichotomised into normal and abnormal (defined as significant urinary incontinence or urinary retention requiring catheterisation).

3. Bowel function:

- Dichotomised into normal and abnormal (either constipation or diarrhoea/incontinence).

4. Adverse events:

- Assessed using the RTOG Acute Radiation Morbidity Scoring Criteria and CTCAE v4.02.

5. Quality of life:

- Measured using the EORTC QLQ-C30 questionnaire.

6. Further treatment and retreatment:

- Surgery, radiotherapy, hormone and chemotherapy.

7. Overall survival:

- Patient NHS numbers will be flagged with the Health & Social Care Information Centre for survival data. Where site becomes aware of event deaths are to be reported to CTC for the 12 months following randomisation.


8. Total number of days spent in hospital/hospice/nursing home/home:

- Following admission with spinal cord compression.

9. Preferred place of care:

- This will be an open question.

Appendix 2.1: Ambulatory status scale question sequence



Appendix 3: Expected adverse events

Certain AEs are expected for radiotherapy^{25, 26}. The following AEs are commonly associated with the trial treatment regimen and will be considered expected.

General side effects of radiotherapy include:

- Fatigue
- Anorexia or reduced appetite
- Erythema in the irradiated field

Side effects following radiotherapy to the spine and pelvis include:

- mucositis in oesophagus, bladder, bowel or rectum, resulting in:
 - Transient sore throat
 - Dysphagia/oesophagitis/discomfort on swallowing from treatment to the cervical and dorsal spine
 - Diarrhoea from treatment to the dorsolumbar spine
 - Nausea from treatment to the dorsolumbar spine

Appendix 4: Protocol version history

Protocol:		Amendments:		
Version no.	Date	Amendment number	Protocol section no	Summary of approval date and main changes from previous version
1.0	18/09/09	n/a	n/a	Approved 3 November 2009 Initial submission to REC
1.1	24/11/09	1 (administrative)	n/a	Approved 3 December 2009 Administrative changes only
2.0	09/09/11	2		<p>Approved 02/11/2011</p> <p>Advice on use of protocol</p> <p>MRC randomisation programme address</p> <p>Update of Secondary endpoints, eligibility criteria and end of trial definition and ff.</p> <p>Update of Trial activation</p> <p>Update of Selection of site investigators, training requirements for site staff, site initiation and activation</p> <p>Update of Informed consent</p> <p>Update of Selection of patients, screening log, pregnancy and randomisation sections</p> <p>Update of Randomisation procedure, Alternative procedures for UK sites, Alternative procedures for non UK sites</p> <p>Addition of Management after treatment withdrawal</p> <p>Update of Assessments, UK Assessment flowchart, Assessment for UK sites, Non UK Assessment flowchart</p> <p>Update of Data management guidelines, completing CRFs, Timelines for data return and submissions moved to 9.4 and data queries to 9.5</p> <p>Safety reporting moved from section 11, administrative changes, addition of overdose section, SAE processing at UCL CTC and to safety monitoring, update to pregnancy section. Deletion of Expectedness section.</p> <p>Addition of Incident reporting section</p> <p>Addition of monitoring sections, oversight committees moved to section 12 from section 10, update to Role of UCL CTC.</p> <p>Withdrawal of patients moved from section 12 to section 13, withdrawal of consent updated.</p> <p>Trial closure moved from section 13 to section 14, updated Early discontinuation and withdrawal from trial participation by site</p> <p>Statistical considerations moved from section 14 to section 15.</p> <p>Ethical and Regulatory approvals updated</p> <p>Sponsorship and indemnity moved from section 15 to section 17 and updated.</p> <p>Funding moved from section 17 to section 18.</p> <p>Publication policy moved from section 18 to section 19.</p> <p>References moved from section 19 to section 20 and updated.</p> <p>Appendix 1: Updated</p> <p>Appendix 2: Updated</p> <p>Appendix 3: Updated</p>

				And minor administrative changes.
3.0	08/08/12	3 (substantial)	Trial summary, Sections 1.1, 2.2.2, 7.0 and appendix 2.1	Update of secondary endpoints
4.0	01/01/13	4 (substantial)	Trial summary Sections 3.1.1, Section 4.0 Section 5.3.1 8.1 9.5 12.0 13.0 15.0	And minor administrative changes Update of eligibility Update of definition of Principal Investigator Update of consent section Update of eligibility Update of assessment of ambulatory status Update of data query procedures Update of Trial monitoring section Update of patient withdrawal and follow up procedures Update of statistical analysis And minor administrative changes.

Supplementary Online Content


Hoskin PJ, Hopkins K, Misra V, et al. Effect of single-fraction vs multifraction radiotherapy on ambulatory status among patients with spinal canal compression from metastatic cancer *JAMA*. doi:10.1001/jama.2019.17913

Supplement 2. Statistical analysis plan

This supplementary material has been provided by the authors to give readers additional information about their work.

SCORAD

STATISTICAL ANALYSIS PLAN

Date prepared	11 Oct 2012
Version number	1.0
Prepared by (trial statistician)	Latha Kadalayil
Reviewed by (trial statistician)	Andre Lopes
Approved by	Allan Hackshaw 
Date approved	13 January 2013

Contents

1. Summary description of the trial
2. Recruitment, follow-up, and baseline characteristics
3. Treatment compliance
4. Efficacy
5. Adverse events
6. Other analyses

1. Summary description of the trial

Trial objectives	To show that ambulatory status using 8Gy in 1 fraction is no worse than with 20Gy in 5 fractions for patients with metastatic spinal cord compression (SCC).
Sample size	700 patients
Intervention arms (what treatments were given)	Randomised phase III trial
	Arm 1: Multiple fraction radiotherapy 20Gy/5f
	Arm 2: Single fraction radiotherapy 8Gy/1f
Primary outcome measure	Ambulatory status at 8 weeks from day 1 of treatment compared to the same at randomisation.
Secondary outcome measures	Recovery of and time to ambulation
	Ambulatory status at 1, 4 and 12 weeks compared to randomisation (where available)
	Maintenance of ambulatory status
	Bladder and bowel function at 1, 4, 8 and 12 weeks from day 1 of treatment compared to randomisation
	Adverse events using RTOG and CTCAE v.4.0 at 1, 4, 8 and 12 weeks from day 1 of treatment
	Quality of life measured using the EORTC QLQ-C30 questionnaire at 1, 4, 8 and 12 weeks from day 1 of treatment compared to the same at randomisation
	Further treatment
	Duration of care in hospital, hospice, nursing home or home
	Preferred place of care
	Overall survival at 12 weeks and 12 months

2. Recruitment, follow-up, and baseline characteristics

The following should be obtained:

- The month and year between which patients were recruited (eg between January 2000 and June 2006)
- The age range of patients recruited (eg 25 to 87 years)
- The number of centres that recruited patients
- The country (or countries) from which patients were recruited
- The length of follow up (patients who have died should be censored). This is obtained for all patients, and in each trial arm (to check that they are similar)
- A table of baseline characteristics, in each trial arm. This should contain age, gender, and any stratification factors used in the randomisation. Other variables could be disease stage, performance status/ECOG score, body weight, and other key biological and physiological measurements.
 - For categorical variables, each column will contain N (%)
 - For continuous variables, each column will contain the mean or median value, and in brackets, the standard deviation or 25-75th centile values
 - P-values for comparing the trial arms should not be reported (see Senn SJ (1994) Testing for baseline balance in clinical trials, *Statistics in Medicine* 13: 1715-1726)
- The number of patients who were ineligible in each trial arm, and the reasons why they were ineligible
- The number of patients who were recruited to the trial but withdrew later on, and the reasons (if available)
- List any possible major protocol violations or ineligibility criteria that would lead to the patient not being included in the analysis, eg patient later found not to have the cancer of interest

3. Treatment compliance

Compliance to radiotherapy

	20 Gy/5 fractions N=?	8 Gy/1 fraction N=?
Exactly as per protocol		
Reasons for non-compliance		
Died during treatment		
Too ill to complete treatment		
Withdrew from trial		
Administrative error		
Other reasons		
Reason 1		
Reason 2		
etc		
Reason not reported		

Reasons for non-compliance contd.....

	20 Gy/5 fractions N=?	8 Gy/1 fraction N=?
Reasons for delay		
reason 1		
reason 2		
etc		
Reasons for interruptions		
reason 1		
reason 2		
etc		
Reasons for dose reduction		
reason 1		
reason 2		
etc		
Reasons for stopping protocol treatment		
reason 1		
reason 2		
etc		

4. Efficacy

The following statistical analyses will be performed:

- Logrank test
- Cox regression modelling (to allow for covariates)
- Kaplan-Meier plots

Check model assumptions:

- Time-to-event data: eg use Schoenfeld residuals or a p-value to test the assumption of proportional hazards
- Continuous data: examine Normal probability plots, and look for a straight line. If very curved, take logs of the data or other transformation

Primary endpoint:

Ambulatory status at 8 weeks from day 1 of treatment compared to randomization (based on evaluable patients).

	Treatment		Risk difference (90% CI) 8 Gy-20Gy	Risk difference (95% CI) 8 Gy-20Gy	P-value
	20 Gy/ 1 fraction N=?	8 Gy/ 5 fractions N=?			
	% (n)				
Evaluable patients					
Positive response					
Maintenance of 1 2 level					
Change from 3 4 to 1 2					
Overall positive response					
Negative response					
Change from 1 2 to 3 4					
Remained at 3 4					
Died before 8 weeks' assessment [#]					
Withdrew from trial/consent					
Not assessed (patient too ill)					
Patient refused assessment					
Lost to follow-up					
Unknown					
Other reasons					
1					
2					
etc					

[#]Percentages based on the total number per treatment arm

Other endpoints

a) Survival analyses

Analyses should be intention-to-treat

	20 Gy/1 fraction N=?	8 Gy/5 fractions N=?
Overall survival (OS)		
Number of deaths		
Median OS (months), 95% CI (or IQR)		
12 weeks' survival rate (95% CI)		
1 year survival rate (95% CI)		
Time to recovery of ambulation*		
Number of events		
Median time to recovery (weeks), 95% CI		
12 weeks' rate (95% CI)		
Time to ambulation**		
Number of events		
Median time to ambulation (months), 95% CI		
12 weeks' rate (95% CI)		

*In those patients with level 3/4 ambulatory status

**In those patients with level 1/2 ambulatory status

For time-to-event data, provide Kaplan-Meier curves, with number of patients at risk in each treatment group below the x-axis.

All time points should start from the date of registration.

Cause of death

	20 Gy/1 fraction N=?	8 Gy/5 fractions N=?
Primary cancer		
Treatment		
Combination of cancer related & treatment related		
Other		
Not known		

b) Change in ambulatory status at 4 and 12 weeks

Similar table as in the primary endpoint (see page 6)

c) Bladder, bowel function at 1, 4, 8 and 12 weeks from day 1 of treatment compared to randomisation

	Baseline		Week 1		Week 4		Week 8		Week 12	
	20 Gy/5 fr N=?	8 Gy/1 fr N=?	20 Gy/5 fr N=?	8 Gy/1 fr N=?	20 Gy/5 fr N=?	8 Gy/1 fr N=?	20 Gy/5 fr N=?	8 Gy/1 fr N=?	20 Gy/5 fr N=?	8 Gy/1 fr N=?
	% (n)									
Bladder function										
Evaluable patients										
Normal										
Abnormal										
Bowel function										
Evaluable patients										
Normal										
Abnormal										

d) Place of care

	Week 1			Week 4			Week 8			Week 12		
	20 Gy/5 fr N=?	8 Gy/1 fr N=?	20 Gy/5 fr N=?	20 Gy/5 fr N=?	8 Gy/1 fr N=?	8 Gy/1 fr N=?	20 Gy/5 fr N=?	8 Gy/1 fr N=?	20 Gy/5 fr N=?	8 Gy/1 fr N=?	8 Gy/1 fr N=?	
	%(n)											
Place of care												
<u>Evaluable patients</u>												
Home/with relatives												
Care home												
Hospital												
Hospice												

e) Further treatment

	Week 1		Week 4		Week 8		Week 12	
	20 Gy/5 fr N=?	8 Gy/1 fr N=?	20 Gy/5 fr N=?	8 Gy/1 fr N=?	20 Gy/5 fr N=?	8 Gy/1 fr N=?	20 Gy/5 fr N=?	8 Gy/1 fr N=?
	% (n)							
Supportive care for SCC								
<u>Evaluable patients</u>								
Corticosteroids								
Analgesics								
Anti-emetics								
Physiotherapy								
Retreatment for SCC								
<u>Evaluable patients</u>								
Surgery								
Chemotherapy								
Radiotherapy								
Treatment for primary or metastatic disease								
<u>Evaluable patients</u>								
Surgery								
Chemotherapy								
Radiotherapy								

5. Adverse events

Present results for the feasibility part and phase III trial separately because safety data are collected differently in the two parts of the trial.

For each type of event, the table will show the number (%) of patients. One patient can appear in more than one row.

a) Grade 3|4 adverse events for Phase III trial patients based on CTCAE v 4.0

Adverse event	Any time	
	20 Gy/ 5 fractions N=?	8 Gy/ 1 fraction N=?
Expected		
Anorexia or reduced appetite		
Diarrhoea		
Nausea		
Dysphagia/Oesophagitis/discomfort on swallowing		
Mucositis in oesophagus, bladder, bowel or rectum		
Erythema in the irradiated field		
Fatigue		
Other		
1		
2		
3		
etc		
Any of the above adverse events*		

*Patients counted only once

b) Similarly list grade 1|2 adverse events.

c) Grade 3|4 adverse events for the feasibility trial patients using RTOG acute toxicity scale

Adverse event	Anytime	
	20 Gy/5 fractions N=?	8 Gy/1 fraction N=?
Skin		
Pharynx and oesophagus		
Larynx		
Lung		
Upper GI		
Lower GI including pelvis		
CNS		
Genitourinary		
Other		
1		
2		
etc		
Any of the above toxicities*		

*Patients counted only once

d) Similarly list grade 1|2 adverse events.

e) List of Serious Adverse Events and SUSARs

6. Other analyses


Subgroup analyses will be provided for the following factors:

Radiotherapy centre
Ambulatory status at randomisation
Primary tumour type
Extent of disease (spinal metastases or spinal and non-bony metastases)

The hazard ratio and 95% CI in each level of the factor would be obtained.

Provide a p-value from a test for interaction between the factor and the treatment allocation, in relation to the main outcome measure (eg interaction between ambulatory status and treatment group using overall survival). This could be done using multivariate Cox modelling (time-to-event data), logistic regression (binary data), or linear regression (continuous data).

If there are several subgroups, a forest plot could be provided. Add a dashed vertical line to indicate the no effect value (eg hazard ratio=1, or relative risk=1), and a solid line to indicate the overall treatment effect (eg hazard ratio from all patients), as in the following example.



Multiple primary endpoints or multiple time points

Use 99% confidence intervals in the subgroup analysis

Multiple time points: use repeated measures analyses (eg mixed modelling), repeated ANOVA

Revision Chronology:			
Version Number	Effective date	Reason for change and Summary of changes	Author
01	13 Oct 2012		Latha Kadalayil
02	13 Jan 2013	Added 90%CI as per design	Andre Lopes

Supplementary Online Content

Hoskin PJ, Hopkins K, Misra V, et al. Effect of single-fraction vs multifraction radiotherapy on ambulatory status among patients with spinal canal compression from metastatic cancer

JAMA. doi:10.1001/jama.2019.17913

eTable 1. Other baseline characteristics by randomization group

eTable 2. Baseline characteristics by randomization group amongst patients evaluable for the primary endpoint

eTable 3. Patients with unknown outcome at 8 weeks' time frame

eTable 4. Sensitivity analyses for the primary endpoint: ambulatory status (AS) at week 8

eTable 5. Causes of death

eTable 6. Adverse events

eTable 7. Bladder and bowel function endpoints

eTable 8. Baseline characteristics by randomization group amongst patients evaluable for the primary endpoint who lived beyond 48 weeks

eTable 9. Ambulatory response at 8 weeks by location of SSC site

eTable 10. Quality of life at 4 and 8 weeks by ambulatory response in 20Gy/5f and 8Gy/1f

eFigure 1. Ambulatory status by randomization group

eFigure 2. Difference in ambulatory status at 8 weeks according to baseline characteristics (99% CIs are shown due to multiple analyses). The protocol pre-specified factors were ambulatory status, primary tumor type and extent of metastases

eFigure 3. Time to loss of ambulation

eFigure 4. Time to recovery of ambulation

eFigure 5. Pain scores in 8Gy/1f and in 20Gy/5f

eFigure 6. Overall survival (hazard ratio) according to baseline characteristics

eFigure 7. Deterioration-free survival

This supplementary material has been provided by the authors to give readers additional information about their work.

Online Only Supplements

Contents

ONLINE ONLY SUPPLEMENTS	1
eTable 1 - Other baseline characteristics by randomization group	3
eTable 2 - Baseline characteristics by randomization group amongst patients evaluable for the primary endpoint.....	4
eTable 3 - Patients with unknown outcome at 8 weeks' time frame.....	5
eTable 4 – Sensitivity analyses for the primary endpoint: ambulatory status (AS) at week 8	6
eTable 5 - Causes of death	10
eTable 6 - Adverse events.....	11
eTable 7 - Bladder and bowel function endpoints	12
eTable 8 - Baseline characteristics by randomization group amongst patients evaluable for the primary endpoint who lived beyond 48 weeks	14
eTable 9 - Ambulatory response at 8 weeks by location of SSC site.....	15
eTable 10 – Quality of life at 4 and 8 weeks by ambulatory response in 20Gy/5f and 8Gy/1f.....	16
eFigure 1 - Ambulatory status by randomization group.....	18
eFigure 2 – Difference in ambulatory status at 8 weeks according to baseline characteristics (99% CIs are shown due to multiple analyses). The protocol pre-specified factors were ambulatory status, primary tumor type and extent of metastases.	19
eFigure 3 – Time to loss of ambulation.....	20
eFigure 4 – Time to recovery of ambulation.....	20
eFigure 5 - Pain scores in 8Gy/1f and in 20Gy/5f	21
eFigure 6 - Overall survival (hazard ratio) according to baseline characteristics	22
eFigure 7 – Deterioration-free survival.....	23

eTable 1 - Other baseline characteristics by randomization group

Baseline characteristics	8 Gy/1f N=345	20 Gy/5f N=341
Bladder function^a		
Normal	246 (71%)	259 (76%)
Abnormal	96 (28%)	82 (24%)
Not reported	3 (1%)	0 (0%)
Bowel function		
Normal	165 (48%)	175 (51%)
Abnormal	177 (51%)	166 (49%)
Constipation	141 (41%)	148 (43%)
Diarrhoea/incontinence	29 (8%)	17 (5%)
Constipation & Diarrhoea/incontinence	7 (2%)	1 (<1%)
Not reported	3 (1%)	0 (0%)
Duration of symptoms before SCC diagnosis^b		
<1 day	13 (4%)	7 (2%)
<1 week	134 (39%)	126 (37%)
<1 month	102 (30%)	104 (31%)
<3 months	37 (11%)	41 (12%)
>3 months	18 (5%)	22 (6%)
Not reported	41 (12%)	41 (12%)

a. Abnormal bladder function is defined as significant urinary incontinence or urinary retention requiring catheterisation

b. Time between onset of symptoms and SCC diagnosis. This data was not collected in the feasibility part of the study.

eTable 2 - Baseline characteristics by randomization group amongst patients evaluable for the primary endpoint

Baseline characteristics	8 Gy/1f N=166	20 Gy/5f N=176	p
Age, years			
Median (range)	71 (44 to 91)	70 (40 to 95)	0.43
Sex			
Male	125 (75%)	123 (70%)	0.26
Site of primary cancer			
Prostate	91 (55%)	91 (52%)	
Lung	15 (9%)	25 (14%)	
Breast	22 (13%)	24 (14%)	
GI	14 (8%)	15 (9%)	
Renal	4 (2%)	6 (3%)	
Skin	4 (2%)	3 (2%)	
Bladder	3 (2%)	1 (1%)	
Gynae, head & neck, sarcoma, unspecified	13 (8%)	11 (6%)	0.83
Extent of metastases			
Nonskeletal mets present	74 (45%)	66 (38%)	0.18
Number of SCC sites			
Single	151 (91%)	165 (94%)	
Multiple	15 (9%)	11 (6%)	0.33
Site of spinal cord compression (SCC)			
Cervical vertebrae	5 (3%)	7 (4%)	
Cervical and thoracic	2 (1%)	4 (2%)	
Thoracic	101 (61%)	113 (64%)	
Thoracic and lumbar	11 (7%)	9 (5%)	
Lumbar	41 (25%)	34 (19%)	
Lumbar and sacrum	1 (1%)	2 (1%)	
Sacrum (S1 and S2)	5 (3%)	5 (3%)	
Not reported	0 (0%)	2 (1%)	0.71
WHO performance status			
0 & 1	65 (39%)	65 (37%)	
2	47 (28%)	46 (26%)	
3	40 (24%)	51 (29%)	
4	13 (8%)	12 (7%)	
Not reported	1 (1%)	2 (1%)	0.85
Ambulatory status			
Grade 1: Ambulatory without walking aids	49 (30%)	49 (28%)	
Grade 2: Ambulatory with walking aids	83 (50%)	83 (47%)	
Grade 3: Unable to ambulate	26 (16%)	33 (19%)	
Grade 4: No motor power	8 (5%)	11 (6%)	0.80
Treatment at baseline			
Chemotherapy only (\leq 4 weeks prior randomization)	6 (4%)	17 (10%)	
Hormone therapy only (\leq 4 weeks prior randomization)	53 (32%)	59 (34%)	
Radiotherapy only (\leq 6 months prior randomization)	13 (8%)	13 (7%)	
Combination of the above	22 (13%)	14 (8%)	
None/Not reported	72 (43%)	73 (41%)	0.19

Note: P value for age derived from quantile regression which compares medians; all the other p-values are derived from chi-square test

eTable 3 - Patients with unknown outcome at 8 weeks' time frame

	Treatment	
	8 Gy/1F	20 Gy/5F
	N=345	N=341
	N (%)	
Unknown outcome at 8 weeks' timeframe^a	179 (51.88%)	165 (48.4%)
Died before week 7	119 (66.5%)	106 (64.2%)
Died between week 7 and week 8	8 (4.5%)	17 (10.3%)
Died between week 8 and week 9	3 (1.7%)	2 (1.2%)
Lost to follow-up before week 7	3 (1.7%)	5 (3.0%)
Lost to follow-up between week 7 and week 8	0 (0%)	0 (0%)
Lost to follow-up between week 8 and week 9	0 (0%)	1 (0.6%)
Alive beyond week 9 (all with baseline assessment):		
Baseline only	4 (2.2%)	0 (0%)
Assessment(s) only before 8 week target ^b	9 (5.0%)	9 (5.5%)
Assessment(s) only after 8 weeks' target ^b	1 (0.6%)	0 (0%)
Assessments only before and only after the 8 weeks' target ^b	32 (17.9%)	25 (15.2%)
^a . 8 weeks' time window is from ≥ 7 weeks to <9 weeks, i.e., ≥ 49 days and <63 days ^b . These patients had assessments outside the protocol specified time window for the 8 weeks assessment		

eTable 4 – Sensitivity analyses for the primary endpoint: ambulatory status (AS) at week 8

Sensitivity analyses	Intention to treat population			Per protocol population		
	8 Gy/1f	20 Gy/5f	Risk difference	8 Gy/1f	20 Gy/5f	Risk difference
	N (%)	N (%)	(90% CI)	N (%)	N (%)	(90% CI)
			8 Gy-20Gy			8 Gy-20Gy
Main analysis (Table 2 of the paper)						
Main analysis by intention to treat and per protocol, where the 8-week assessment is defined as any occurring between 49 and 62 days inclusive post-randomization (i.e. at weeks 7 or 8)						
Evaluables	166	176	-3.5%	164	173	-3.9%
Positive response	115 (69.3%)	128 (72.7%)	(-11.5 to 4.6)	114 (69.5%)	127 (73.4%)	(-12.0 to 4.2)
Analysis 1a (primary analysis adjusted for the randomization stratification factors: baseline ambulatory status, primary tumour and extension of metastases)						
<ul style="list-style-type: none"> Logistic regression was implemented with the outcome being a positive response at 8 weeks, and explanatory variables being treatment and minimisation stratification factors. The adjusted probabilities of positive response by treatment, the difference in these probabilities and estimated 90%CI for the difference were derived from the logistic regression. 						
Evaluables	166	176	-4.8%	164	173	-5.3%
Positive response	68.5%	73.3%	(-11.8 to 2.2%)	68.7%	74.0%	(-12.3% to 1.7)
Analysis 1b (primary analysis using clustered sandwich estimator)						
<ul style="list-style-type: none"> Logistic regression was implemented with standard errors adjusted for hospital (clustered sandwich estimator which allows for intragroup correlation) and fit with the outcome being a positive response at 8 weeks and explanatory variable being treatment. The probabilities of positive response by treatment, the difference in these probabilities and estimated 90%CI for the difference were derived from the logistic regression. 						
Evaluables	166	176	-3.5%	164	173	-3.9%
Positive response	69.3%	72.7%	(-10.3 to 3.4%)	69.5%	73.4%	(-11.5% to 3.7)
Analysis 2 (handling patients without the 8-week assessment)						
40 patients were assessed between 63 and 69 days post-randomization (i.e. up to 1 week after the 62-day limit) so were not included in the main analysis above. The sensitivity analysis includes these patients. The analysis is therefore based on patients with an AS assessment between 49 and 69 days post-randomization.						
Evaluables	191	191	-4.2	188	188	-4.8
Positive response	131 (68.6%)	139 (72.8%)	(-11.8 to 3.5)	129 (68.6%)	138 (73.4%)	(-12.5 to 2.9)
Analysis 3 (handling patients without the 8-week assessment)						
57 patients were assessed at 4 weeks and also after week 8 (i.e. after 62 days post-randomization). However, 51 of these had the same ambulatory response at both time points, so it was assumed that their 8-week assessment would be the same also. The other 6 patients were not included here.						
Evaluables	195	198	-4.0	192	195	-4.6
Positive response	134 (68.7%)	144 (72.7%)	(-11.6 to 3.5)	132 (68.8%)	143 (73.3%)	(-12.2 to 3.0)
Analysis 4 (imputation of missing data)						
This analysis assumes that the following categories of patients had a negative response (N=89):						
<ul style="list-style-type: none"> All patients alive beyond week 9 with no ambulatory assessment at week 8 time window (49-62 days post-randomization) 						

• All patients lost to follow-up before week 9 and therefore with no ambulatory assessment at week 8 time window							
Evaluables	215	216	-5.8		211	213	-5.6
Positive response	115 (53.5%)	128 (59.3%)	(-13.6 to 2.1)		114 (54.0%)	127 (59.6%)	(-13.5 to 2.3)
Analysis 5 (imputation of missing data)							
This analysis assumes that the following categories of patients had a positive response (N=89):							
• All patients alive beyond week 9 with no ambulatory assessment at week 8 (49-62 days post-randomization)							
• All patients lost to follow-up before week 9 and therefore with no ambulatory assessment at week 8 time window							
Evaluables	215	216	-1.5		211	213	-2.1
Positive response	164 (76.3%)	168 (77.8%)	(-8.2 to 5.2)		161 (76.3%)	167 (78.4%)	(-8.8 to 4.6)
Analysis 6 (imputation of missing data)							
This analysis assumes that the following categories of patients had the same positive response rate at week 8 as the rate observed in the intention-to-treat analysis in the 8Gy/1f group (N=89):							
• All patients alive beyond week 9 (≥63 days post-randomization) with no ambulatory assessment at week 8							
• All patients lost to follow-up before week 9 with no ambulatory assessment at week 8 time window							
Evaluables	215	216	-2.9		211	213	-3.6
Positive response	149 (69.3%)	156 (72.2%)	(-10.1 to 4.3)		146 (69.2%)	155 (72.8%)	(-10.8 to 3.7)
Analysis 7 (imputation of missing data)							
This analysis assumes that the following categories of patients had the same positive response rate at week 8 as the rate observed in the intention-to-treat analysis in the 20Gy/5f group (N=89):							
• All patients alive beyond week 9 with no ambulatory assessment at week 8							
• All patients lost to follow-up before week 9 with no ambulatory assessment at week 8							
Evaluables	215	216	-2.5		211	213	-3.0
Positive response	151 (70.2%)	157 (72.7%)	(-9.6 to 4.7)		148 (70.1%)	156 (73.2%)	(-10.3 to 4.1)
Analysis 8 (imputation of missing data)							
This analysis considers the following:							
• If a patient has the same ambulatory assessment before and after the week 8 time period and the patient does not have an assessment done during week 8 (as defined), it is assumed that the week 8 assessment is the same as the response the patient obtained before and after the week 8 time period (N=51).							
• All the patients with no ambulatory assessment at week 8 (a) alive beyond week 9 and (b) lost to follow-up before week 9 are assumed to have the same rate of positive response as the ones with known ambulatory status at the week 8 time period (N=38)							
Evaluables	215	216	-3.9		211	213	-4.1
Positive response	148 (68.8%)	157 (72.7%)	(-11.1 to 3.4)		146 (69.2%)	156 (73.2%)	(-11.3 to 3.2)
Analysis 9 (Multiple imputation using chained equations - outcome imputed as a binary variable)							
The data for the following category of patients were imputed using multiple imputation (N=89 for ITT and N=87 for PP):							
• All patients alive beyond week 9 with no ambulatory assessment at week 8 (49-62 days post-randomization)							
• All patients lost to follow-up before week 9 and therefore had no ambulatory assessment at week 8.							
The multiple imputation was done considering the following:							

- The auxiliary variables used were: age, sex, primary tumour, ambulatory status at randomization, the extent of metastases, number of SSC sites, site of spinal cord compression, recruiting country, hospital site and treatment group.
- 50 imputations were used in the procedure using a random seed.
- A direct multiple imputation of the binary outcome response at 8 weeks (AS response at 8 weeks as positive or negative) was done using logistic regression.
- An unadjusted logistic regression model was estimated using multiple imputations in order to evaluate the association between treatment group and response at 8 weeks.
- The predicted odds ratios and 90%CI from logistic regression using multiple imputations were converted into the difference in predicted probabilities and estimated 90%CI.

Evaluables	215	216	-4.4%		211	213	-5.0%
Positive response	65.3%	69.7%	(-12.5% to 3.6%)		65.1%	70.2%	(-13.4% to 3.3%)

Analysis 10 (Multiple imputation using chained equations - outcome imputed directly as an ordinal variable)

The data for the following categories of patients were imputed using multiple imputation (N=89 for ITT and N=87 for PP):

- All patients alive beyond week 9 with no ambulatory assessment at week 8 (49-62 days post-randomization)
- All patients lost to follow-up before week 9 and therefore had no ambulatory assessment at week 8 time window

The multiple imputation was done considering the following:

- The auxiliary variables used were: age, sex, primary tumour, ambulatory status at randomization, the extent of metastases, number of SSC sites, site of spinal cord compression, recruiting country, hospital site and treatment group.
- 50 imputations were used in the procedure using a random seed.
- Multiple imputation of the ordinal outcome at 8 weeks (AS 1,2,3,4) was carried out using an ordered logistic regression imputation method. Once the ordinal outcome was imputed, it was then transformed into a binary variable (positive/negative response) defined in the protocol.
- An unadjusted logistic regression model was estimated using multiple imputations to evaluate the association between treatment group and response at 8 weeks.
- The predicted odds ratios and 90%CI from logistic regression using multiple imputations were converted into difference in predicted probabilities and estimated 90%CI to be in line with the primary analysis results.

Evaluables	215	216	-3.4%		211	213	-4.4%
Positive response	65.5%	68.9%	(-11.7% to 4.9%)		65.9%	70.3%	(-12.5% to 3.7%)

Analyses 4 to 10 are based on the 8 week assessment defined as between 49 and 62 days inclusive post-randomization.

The population used for the intention to treat analysis includes all eligible randomised patients who did not die by the week 8 timepoint. The population used for the per protocol analysis includes all eligible randomised patients who received treatment as per protocol who did not die by the week 8 timepoint

eTable 5 - Causes of death

Cause of death	Deaths	
	N=529	
	8Gy/1f	20Gy/5f
	N (%)	N (%)
	N=266	N=263
Progressive Cancer	226 (85%)	220 (83%)
Other:		
Infections and infestations	4 (2%)	4 (2%)
Cardiovascular disorders	1 (<1%)	5 (2%)
Other ^a	5 (2%)	6 (2%)
Uncertain/Not Known	30 (11%)	28 (11%)
^a . Other: 8Gy1f: (1) disease progression; (2) Injury, poisoning and procedural complications; (1) metabolism and nutrition disorder; (1) nervous system disorder 20Gy5f: (3) disease progression; (1) Injury, poisoning and procedural complications; (1) General disorders and administration site conditions; (1) Secondary Cancer		

eTable 6 - Adverse events

Adverse events	Grade 1 & 2		Grade 3 & 4 ^a	
	N=686		N=686	
	8Gy/1f N=345	20Gy/5f N=341	8Gy/1f N=345	20Gy/5f N=341
Skin				
Radiation reaction	40 (11.6%)	66 (19.4%)		1 (0.3%)
Other	9 (2.6%)	3 (0.9%)		2 (0.6%)
Musculoskeletal				
Pain	35 (10.1%)	33 (9.7%)	18 (5.2%)	9 (2.6%)
Edema	7 (2.0%)	6 (1.8%)		
Muscle weakness	5 (1.4%)	5 (1.5%)	3 (0.9%)	4 (1.2%)
Other	2 (0.6%)			1 (0.3%)
Gastrointestinal				
Anorexia	101 (29.3%)	101 (29.6%)	6 (1.7%)	4 (1.2%)
Nausea	65 (18.8%)	63 (18.5%)	4 (1.2%)	1 (0.3%)
Diarrhoea	49 (14.2%)	36 (10.6%)	2 (0.6%)	6 (1.8%)
Dysphagia	23 (6.7%)	32 (9.4%)	3 (0.9%)	
Constipation	22 (6.4%)	12 (3.5%)	1 (0.3%)	
Sore throat	13 (3.8%)	33 (9.7%)		
Vomiting	3 (0.9%)	8 (2.3%)	2 (0.6%)	
Abdominal pain		4 (1.2%)	2 (0.6%)	1 (0.3%)
Abdominal distension	1 (0.3%)		2 (0.6%)	
Oral pain	3 (0.9%)	2 (0.6%)		
Other	19 (5.5%)	25 (7.3%)		1 (0.3%)
CNS				
Fatigue	168 (48.7%)	189 (55.4%)	28 (8.1%)	33 (9.7%)
Headache	3 (0.9%)			
Other	12 (3.5%)	14 (4.1%)	9 (2.6%)	5 (1.5%)
Blood and lymphatic				
Anaemia	1 (0.3%)	1 (0.3%)		2 (0.6%)
Febrile neutropenia				1 (0.3%)
Other	1 (0.3%)	1 (0.3%)	1 (0.3%)	2 (0.6%)
Other				
Respiratory	11 (3.2%)	16 (4.7%)	12 (3.5%)	13 (3.8%)
Urinary	10 (2.9%)	10 (2.9%)	4 (1.2%)	1 (0.3%)
Infective	6 (1.7%)	9 (2.6%)	3 (0.9%)	2 (0.6%)
Psychiatric	9 (2.6%)	5 (1.5%)	1 (0.3%)	4 (1.2%)
Metabolic	1 (0.3%)		1 (0.3%)	3 (0.9%)
Renal	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
Thromboembolic and other vascular	1 (0.3%)	2 (0.6%)	1 (0.3%)	1 (0.3%)
Other	4 (1.2%)	4 (1.2%)	7 (2.0%)	3 (0.9%)
Any adverse event	179 (51.9%)	194 (56.9%)	71 (20.6%)	70 (20.5%)

^a. Three patients had grade 5 adverse event in 8Gy/1f Group: (1) Intracranial haemorrhage (Nervous system disorders); (1) Supraventricular tachycardia (Cardiac disorders) and Thromboembolic event (Vascular disorders); (1) Sudden death NOS (General disorders and administration site conditions)
 Five patients had grade 5 adverse event in 20Gy/5f Group: (1) Myocardial infarction (Cardiac disorders); (1) Upper respiratory infection (Infections and infestations) and Other injury, poisoning and procedural complications: Hospital-acquired upper respiratory tract infection (Injury, poisoning and procedural complications); (1) Stridor (Respiratory, thoracic and mediastinal disorders); (1) Cardiac arrest (Cardiac disorders); (1) Respiratory failure (Respiratory, thoracic and mediastinal disorders)
 All of the above 8 deaths were unrelated to radiotherapy

Note: Each row represents the number of patients that experienced a particular type of adverse event. On each row patients are counted only once based on the worst grade experienced for each adverse event.

eTable 7 - Bladder and bowel function endpoints

Assess ment	Abnormal bladder function				Abnormal bowel function			
	8Gy/1f	20Gy/5f	Odds ratios (95%CI)	p	8Gy/1f	20Gy/5f	Odds ratios (95%CI)	p
	Events/ N (%)	Events/N (%)			Events/ N (%)	Events/N (%)		
Overall								
Baseline	96/342 (28%)	82/341 (24%)	1.23 (0.88 to 1.74)	0.2 3	177/342 (52%)	166/341 (49%)	1.13 (0.84 to 1.53)	0.4 2
Week 1	93/294 (32%)	76/300 (25%)	1.36 (0.95 to 1.95)	0.0 9	131/293 (45%)	132/300 (44%)	1.03 (0.74 to 1.42)	0.8 6
	Adjusted ^a		1.15 (0.67 to 1.99)	0.6 1				
Week 4	66/209 (32%)	53/223 (24%)	1.48 (0.97 to 2.26)	0.0 7	82/209 (39%)	79/223 (35%)	1.18 (0.80 to 1.74)	0.4 1
	Adjusted ^a		1.61 (0.92 to 2.82)	0.0 9				
Week 8	47/151 (31%)	34/166 (20%)	1.75 (1.05 to 2.92)	0.0 3	59/151 (39%)	61/166 (37%)	1.10 (0.70 to 1.74)	0.6 7
	Adjusted ^a		1.78 (0.93 to 3.39)	0.0 8				
Week 12	41/139 (30%)	35/154 (23%)	1.42 (0.84 to 2.40)	0.1 9	53/140 (38%)	55/155 (35%)	1.11 (0.69 to 1.78)	0.6 7
	Adjusted ^a		1.64 (0.86 to 3.14)	0.1 4				
Any time ^b	132/316 (42%)	111/322 (34%)	1.36 (0.99 to 1.88)	0.0 6	203/315 (64%)	204/322 (63%)	1.05 (0.76 to 1.45)	0.7 8
	Adjusted ^a		1.31 (0.87 to 1.97)	0.2 0				
Only location of SSC site within C1 to T12 (treatment exclusively to the spinal cord)								
Week 8	29/97 (30%)	29/117 (25%)	1.29 (0.70 to 2.37)	0.4 0	41/97 (42%)	46/117 (39%)	1.13 (0.65 to 1.95)	0 . 6 6
Any time	92/219 (42%)	85/236 (36%)	1.29 (0.88 to 1.88)	0.1 9	143/219 (65%)	148/236 (63%)	1.12 (0.76 to 1.64)	0 . 5 7
Only location of SSC site within L1 to S2 (treatment to the cauda equina)								
Week 8	15/44 (34%)	4/39 (10%)	4.53 (1.35 to 15.14)	0.0 14	14/44 (32%)	11/39 (28%)	1.19 (0.46 to 3.05)	0 . 7 2
Any time	34/81 (42%)	21/70 (30%)	1.69 (0.86 to 3.32)	0.1 3	51/80 (64%)	47/70 (67%)	0.86 (0.44 to 1.69)	0 . 6 6
Only location of SSC site within T6 to L5 (treatment across both the cord and cauda equina)								
Week 8	3/10 (30%)	1/8 (13%)	3.00 (0.25 to 36.32)	0.3 9	4/10 (40%)	3/8 (38%)	1.11 (0.16 to 7.51)	0 . 9 1
Any time	6/16 (38%)	5/14 (36%)	1.08 (0.24 to 4.79)	0.9 2	9/16 (56%)	7/14 (50%)	1.29 (0.30 to 5.43)	0

									7
									3

Note: Logistic regression was done comparing 8Gy/1f versus 20Gy/5f. The analysis was based only on the number of patients with assessment (evaluable patients)

- a. Adjusted for bladder function at baseline, sex, age, baseline AS, primary tumour, number of SSC sites, the extent of metastases at baseline and extent of metastases
- b. Includes assessments at all time points except baseline assessment

eTable 8 - Baseline characteristics by randomization group amongst patients evaluable for the primary endpoint who lived beyond 48 weeks

Baseline characteristics	8 Gy/1f N=39	20 Gy/5f N=38	p
Age, years			
Median (range)	68 (51 to 86)	71 (40 to 91)	0.4
Sex			
Female	10 (26%)	6 (16%)	
Male	29 (74%)	32 (84%)	0.4
Site of primary cancer			
Prostate	26 (67%)	30 (79%)	
Lung	1 (3%)	0 (0%)	
Breast	7 (18%)	3 (8%)	
GI	1 (3%)	1 (3%)	
Renal	1 (3%)	0 (0%)	
Skin	0 (0%)	1 (3%)	
Bladder	0 (0%)	1 (3%)	
Gynae, head & neck, sarcoma, unspecified	3 (8%)	2 (5%)	0.59
Extent of metastases			
Nonskeletal mets absence	25 (64%)	29 (76%)	
Nonskeletal mets present	14 (36%)	9 (24%)	0.32
Number of SCC sites			
Single	37 (95%)	36 (95%)	
Multiple	2 (5%)	2 (5%)	>0.99
Site of spinal cord compression (SCC)			
Cervical vertebrae	1 (3%)	1 (3%)	
Cervical and thoracic	1 (3%)	0 (0%)	
Thoracic	22 (56%)	23 (61%)	
Thoracic and lumbar	3 (8%)	4 (11%)	
Lumbar	10 (26%)	8 (21%)	
Lumbar and sacrum	1 (3%)	1 (3%)	
Sacrum (S1 and S2)	1 (3%)	1 (3%)	0.98
WHO performance status			
0 & 1	19 (49%)	18 (47%)	
2	11 (28%)	8 (21%)	
3	9 (23%)	9 (24%)	
4	0 (0%)	2 (5%)	
Not reported	0 (0%)	1 (3%)	0.59
Ambulatory status			
Grade 1: Ambulatory without walking aids	13 (33%)	13 (34%)	
Grade 2: Ambulatory with walking aids	21 (54%)	15 (39%)	
Grade 3: Unable to ambulate	4 (10%)	8 (21%)	
Grade 4: No motor power	1 (3%)	2 (5%)	0.48
Treatment at baseline			
Chemotherapy only (\leq 4 weeks prior randomization)	1 (3%)	1 (3%)	
Hormone therapy only (\leq 4 weeks prior randomization)	16 (41%)	19 (50%)	
Radiotherapy only (\leq 6 months prior randomization)	0 (0%)	4 (11%)	
Combination of the above	6 (15%)	2 (5%)	
None	16 (41%)	12 (32%)	0.06

Note: P value for age derived from quantile regression which compares medians; all the other p-values are derived from Fishers' exact test

eTable 9 - Ambulatory response at 8 weeks by location of SSC site

	Intention to treat population				Per protocol population		
	8 Gy/1f	20 Gy/5f	Risk difference		8 Gy/1f	20 Gy/5f	Risk difference
	N (%)	N (%)	(90% CI)		N (%)	N (%)	(90% CI)
			8 Gy-20Gy				8 Gy-20Gy
Group 1 - Location of SSC site within C1 to T12							
Evaluables	108	124	-1.0%		108	122	-1.3%
Positive response	73 (67.6%)	85 (68.6)	-11.1% to 9.1%		73 (67.6%)	84 (68.9%)	-11.4% to 8.9%
Group 2 - Location of SSC site within L1 to S2							
Evaluables	47	41	-8.8%		46	40	-9.2%
Positive response	36 (76.6%)	35 (85.4%)	-22.4% to 4.9%		36 (78.3%)	35 (87.5%)	-22.4% to 4.0%
Group 3 - Location of SSC site within T6 to L5							
Evaluables	11	9	-12.1%		10	9	-16.7%
Positive response	6 (54.6%)	6 (66.7%)	-47.9% to 23.6%		5 (50.0%)	6 (66.7%)	-53.3% to 20.0%

Note: The total is 340 instead of 342 because two patients had unknown location of SSC site (it was not reported at baseline)


eTable 10 – Quality of life at 4 and 8 weeks by ambulatory response in 20Gy/5f and 8Gy/1f

Quality of Life scales by ambulation status	Ambulatory response				Mean difference adjusted for QoL baseline scores	
	(Grade 1-2)		(Grade 3-4)			
	N	Mean	N	Mean	(1-2) vs (3-4)	p
					(95%CI)	
QoL at 4 weeks according to ambulatory response at 4 weeks						
20Gy/5f						
Global health status	99	45.3	37	27.0	13.4(5.3 to 21.5)	0.001
Physical functioning	98	44.4	37	6.9	21.9(13.6 to 30.1)	p<0.0001
Role functioning	98	34.4	37	2.7	23.2(13.1 to 33.3)	p<0.0001
Emotional functioning	99	74.4	37	69.1	2.0(-7.2 to 11.1)	0.67
Cognitive functioning	99	75.6	37	64.9	7.4(-1.9 to 16.7)	0.12
Social functioning	98	49.5	37	14.4	23.0(11.0 to 35.0)	p<0.0001
8Gy/1f						
Global health status	105	46.8	39	28.0	15.2(7.5 to 22.9)	p<0.0001
Physical functioning	105	43.4	39	3.2	29.6(20.9 to 38.4)	p<0.0001
Role functioning	103	33.5	38	4.0	25.6(15.2 to 36.0)	p<0.0001
Emotional functioning	105	74.0	39	66.3	7.5(-0.8 to 15.7)	0.08
Cognitive functioning	105	79.0	39	66.7	8.6(-0.01 to 17.1)	0.05
Social functioning	105	40.3	39	18.6	16.0(5.3 to 26.7)	0.004
QoL at 8 weeks according to ambulatory response at 8 weeks						
20Gy/5f						
Global health status	81	48.6	26	33.0	14.0(4.3 to 23.7)	0.005
Physical functioning	82	43.7	26	6.9	27.6(17.2 to 38.0)	p<0.0001
Role functioning	81	34.6	27	8.0	24.0(11.7 to 36.3)	p<0.0001
Emotional functioning	82	74.2	26	69.6	0.8(-8.7 to 10.1)	0.88
Cognitive functioning	82	77.0	26	75.6	1.3(-8.7 to 11.2)	0.80
Social functioning	81	50.0	26	11.5	32.1(18.8 to 45.6)	p<0.0001
8Gy/1f						
Global health status	83	45.9	22	31.8	11.0(-1.0 to 23.0)	0.07
Physical functioning	83	45.5	22	3.2	34.5(21.4 to 47.7)	p<0.0001
Role functioning	82	35.9	22	5.3	27.2(12.8 to 41.7)	p<0.0001
Emotional functioning	82	70.0	22	61.0	5.3(-7.5 to 18.1)	0.41
Cognitive functioning	82	74.3	22	69.7	1.8(-11.0 to 14.6)	0.78
Social functioning	82	45.7	22	18.2	18.1(2.2 to 34.0)	0.03

Ambulatory status - Grade 1-2: able to walk/mobile. Grade 3-4: unable to walk easily/not mobile.

All QoL scores are on a scale 0-100, where a high score indicates good health. Hence a positive mean difference indicates that QoL is better among patients with ambulatory grades 1-2.


eFigure 1 - Ambulatory status by randomization group




Note: Week 1 is between day 7 and 13 inclusive after randomization. Week 4 is between day 21 to 34 inclusive after randomization. Week 8 is between day 49 to 62 inclusive after randomization. Week 12 is between day 70 to 97 inclusive after randomization.

* These time points were outside the protocol specified time frames for the assessments and are shown here for completeness

eFigure 2 – Difference in ambulatory status at 8 weeks according to baseline characteristics (99% CIs are shown due to multiple analyses). The protocol pre-specified factors were ambulatory status, primary tumor type and extent of metastases.




eFigure 3 – Time to loss of ambulation




Note: Proportionality assumption test p=0.96

eFigure 4 – Time to recovery of ambulation



Note: Proportionality assumption test p=0.55

eFigure 5 - Pain scores in 8Gy/1f and in 20Gy/5f




Note: Week 1 is between day 7 and 13 inclusive after randomization. Week 4 is between day 21 to 34 inclusive after randomization. Week 8 is between day 49 to 62 inclusive after randomization. Week 12 is between day 70 to 97 inclusive after randomization.


* These time points were outside the protocol specified time frames for the assessments and are shown here for completeness.

The figure shows the mean pain score at each time point, adjusted for the baseline score, from a repeated measures mixed model that included an interaction term between time and treatment group.

eFigure 6 - Overall survival (hazard ratio) according to baseline characteristics



eFigure 7 – Deterioration-free survival



An event is any patient who had ambulatory status grade 1 or 2 at baseline who then deteriorated to grade 3-4 during the trial (mostly within the 12-week time frame, but some assessments went beyond this), or had died at any time, whichever came first. Patients whose ambulatory status did not progress to grade 3 or 4 (mostly within 12 weeks) and did not die were censored at the date last seen alive (acknowledging that some of these patients may have progressed to grade 3-4 after their last ambulatory assessment but we do not have this information).

Data Sharing Statement

Hoskin. Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer. *JAMA*. Published December 03, 2019. 10.1001/jama.2019.17913

Data

Data available: No